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Sensitisation of sensory neurones by prostanoids, especially prostaglandin E2 (PGE2), is 
、 
well recognised as a factor in the hyperalgesic activity of these compounds. Recent 
reports from receptor-knockout studies indicate that prostacyclin rather than PGE2 is the 
major prostanoid involved in inflammatory pain, supporting observations of high level 
expression ofprostacyclin (IP)-receptor mRNA in the dorsal root ganglia (DRG) ofmice. 
Therefore, the present study was designed to characterise prostacyclin receptors of adult 
male rat DRG cells in vitro, and wherever possible to compare these results with those of 
PGE2 acting via EP-receptors. 
Different DRG cell isolation procedures were initially compared to maximise cell yield 
and purity. Preliminary experiments looking at Ca�+ signalling suggested that the IP-
receptors are indeed located neuronally, with approximately 75% of capsaicin-sensitive 
(i.e. nociceptive) neurones responding also to the IP-receptor agonist iloprost. Using 
cyclic AMP assays to characterise the receptors in detail, DRG cells were found to 
possess IP and EP2/4-receptors, but not EP3-recept0rs. Surprisingly, the maximum 
response of DRG cells to agonists was inversely dependent on cell density. Both IP and 
EP2/4-receptors were demonstrated to undergo homologous desensitisation, but the 
endogenous production ofprostanoids could not account for these cell density-dependent 
results. Attempts to identify a Gj-mediated process to account for these results has so far 
been unsuccessful. While the neuropeptide calcitonin gene-related peptide (CGRP) could 
be detected in DRG cells, we were unable to detect any stimulated release ofCGRP. 
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論 文 摘 要 
一系列的前列腺素（prostanoids )，特別是前列腺素仏(PGE:), 
可引起感覺神經元致敏，他們在痛覺過敏過程中的作用巳經被充份 
認識。近期受體k n o c k out研究報告指出，前列環素（PGl2)，而非 
PGE2，是參與炎性疼痛的主要前列腺素。此結果和在小鼠背根神經 













胞内的降釣素基因相關肽（C G R P )的反應性釋放。 
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Prostanoids, which include prostaglandins (PGs) and thromboxanes (TXs) are products of 
arachidonic acid metabolism by cyclooxygenase (COX) and are responsible for 
mediating various physiological and pathophysiological stimuli (Coleman et al., 1984; 
Needleman et al, 1986). Since prostanoids are released outside of the cell immediately 
after synthesis and have a short biological half-life, they are ideally suited to act as 
controllers of local homeostasis (Ushikubi et al., 1995). Amongst the most studied of 
prostaglandin's actions are their effect on smooth muscle contraction and relaxation and 
their effect on platelet aggregation (Coleman et al, 1994a). These effects are mediated 
via specific cell surface receptors which are classified into five basic types, based on 
sensitivity to the five primary prostanoids, prostaglandin D2 (PGD2), prostaglandin E2 
(PGE2) prostaglandin Fia (PGF2a), prostacyclin (PGI2) and thromboxane A2 (TXA2), 
termed DP, EP，FP, IP and TP-receptors, respectively (Coleman et al., 1990). In this 
chapter a briefdescription ofprostanoid biosynthesis and metabolism will be discussed in 
addition to the diverse roles of the individual prostaglandin receptors. 
1.2 Prostanoid biosynthesis and metabolism 
Prostanoids are formed from one of three fatty acid substrate types, dihomo-y-linolenic 
acid (series 1)，arachidonic acid (series 2) and timodonic acid (series 3). Of these three 
substrates, arachidonic acid is the most abundant and is formed following 
glycophospholipid de-esterification，probably by phospholipase A2 (Coleman et al, 
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1990). Once formed, arachidonic acid is converted by the COX activity of the enzyme 
endoperoxide synthase into prostaglandin G2 (PGG2), which in turn is reduced to form 
prostaglandin H2 (PGH2) by the hydroperoxidase activity of endoperoxide synthase 
(Smith, 1989). Finally, metabolism of PGH2 results in formation of the biologically 
active "primary prostanoids" PGD2, PGE2, PGF2a, PGI2 and TXA2. Prostacyclin is 
formed from PGH2 with the aid of a cytochrome P-450 type enzyme, named PGI2 
synthase (Coleman et al, 1994a). Prostaglandin E2 is transformed from PGH2 by the 
isomerase enzyme PGE2 synthase, which is found widely distributed in mammalian 
tissues, whilst PGD2 formation is catalysed by serum albumin released from platelets 
(Coleman et al, 1990). Thromboxane A2, like PGI2, is formed with the aid of a 
cytochrome P-450 type enzyme, thromboxane synthase and PGF2a by a reductase 
enzyme (Coleman et al., 1990). Once formed these prostanoids are rapidly metabolised 
by various enzymes. This enzymatic breakdown of prostanoids consists of two steps: 
firstly the rapid reduction or abolition of the biological effects of the prostanoid, followed 
by the slower oxidation of these compounds in order to facilitate renal clearance. PGE2 
and PGFia undergo rapid dehydrogenation into i5-keto-PGE2 and i5-keto-PGF2a 
metabolites respectively (Anggard & Flower, 1993). In the case of PGD2, a 9-keto-
reductase enzyme forms 9a,lip-PGF2, which has substantial biological activity on FP-
receptors before further metabolic breakdown. Prostacyclin and TXA2 are extremely 
unstable and are rapidly hydrolysed without the aid of enzymes into 6-keto-PGFia and 
thromboxane B2, respectively (Anggard & Flower, 1993). 
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1.3 Prostaglandin receptors 
As mentioned previously, prostaglandin receptors are divided into five basic types based 
on sensitivity to the five primary prostanoids, and are termed DP, EP, FP, IP and TP-
receptors, respectively (Coleman et al, 1990). Of these prostanoid receptors, EP-
receptors are known to possess 4 receptor subtypes named EPi, EP2, EP3 and EP4, all of 
which respond to the naturally occurring agonist PGE2. It has also been suggested 
recently that there may be two IP-receptor subtypes, one being the classical platelet type 
IP-receptor and the second found in the central nervous system (Takechi et al, 1996). All 
prostanoid receptors possess seven transmembrane spanning domains and are thus 
members ofthe rhodopsin-type superfamily of G protein-coupled receptors. 
1.3.1 DP-receptors 
DP-receptors are largely distributed in blood platelets, vascular smooth muscle and 
nervous tissue. Responses mediated by DP-receptors are mostly inhibitory, e.g. inhibition 
of platelet aggregation and relaxation of smooth muscle (Coleman et al, 1994a). 
However, DP-receptors are sometimes associated with excitatory events in some sensory 
neurones, where they can modulate hyperalgesia (Horiguchi et al, 1986). DP-receptors 
r 
mediate their responses by stimulating adenylate cyclase activity via Gs, and thereby 
cause an increase in cyclic AMP production. No research has been carried out to 
determine the localisation of DP-receptors on rat DRG cells, but recent investigations 
have demonstrated that stimulation ofrat DRG cells with PGD2 had a negligible effect on 
cyclic AMP production (Smith et al, 1998). 
3 
1.3.2 EPi-receptors 
EPi-receptors are mostly found in smooth muscle cells of the trachea and gastrointestinal 
tract, and are known to cause contraction of these tissues due to Ca�+ mobilisation 
(Coleman et al, 1994a). However, stimulation of rabbit cortical collecting tube (RCCT) 
cells with PGE2 was shown to cause Ca�+ mobilisation, without affecting inositol 1,4,5-
triphosphate production suggesting a PLC-independent mechanism (Coleman et al, 
1994a). In situ hybridisation studies have also demonstrated the presence ofEP!-receptor 
mRNA in DRG neurones of mice (Oida et al, 1995) but the exact role of EPi-receptors 
in DRG cells is yet to be determined. 
1.3.3 EP2-recept0rs 
‘ EP2-receptors are widely distributed in smooth muscle cells such as trachea and blood 
vessels, and cause relaxation of the tissue when stimulated (Coleman et al, 1994a). To 
date there are no reports regarding the localisation of EP2-recept0r mRNA in DRG cells, 
although there have been reports of [^]-PGE2 binding sites present at low density in rat 
DRG, it is currently unknown which of the EP-receptor subtypes is responsible for the 
binding (Matsumura et al, 1995). 
EP2-recept0rs are known to positively couple to adenylate cyclase via Gs, and will 
result in production of cyclic AMP following stimulation of the receptor (Simon et al., 
1980). Stimulation of DRG cells with PGE2 results in cyclic AMP production with an 
EC50 value of 120 nM (Smith et al, 1998). However, this relatively low potency could 
suggest that this response is due to stimulation of other Gs coupled prostanoid receptors 
by PGE2 or co-stimulation of EP3-recept0rs, which are negatively coupled to adenylate 
cyclase. Unfortunately in the absence of any specific EP2-recept0r antagonists, it is 
difficult to determine ifthis is indeed the case. However, one possible solution would be 
4 
to use EP3-recept0r knockout mice to confirm that co-stimulation of EP3 does not occur 
(Ushikubi et al, 1998). 
l73.4 EP3-recept0rs 
EP3-recept0rs are widely distributed and are responsible for contraction of 
gastrointestinal, uterine and vascular smooth muscle (Lawrence et al, 1992; Coleman et 
al” 1994a)，and are also thought to be involved with inhibition of acid secretion from the 
gastric mucosa and inhibition of neurotransmitter release from peripheral autonomic 
nerves (Coleman et al, 1994a). EP3-recept0r mRNA has also been identified on mouse 
DRG cells (Oida et al, 1995) and on rat DRG slices O^^antel, F. et al, 1999，personal 
communication). However, subsequent studies have demonstrated that the EP3-selective 
agonist sulprostone had no effect on cyclic AMP production in rat DRG cells, suggesting 
that there are no functional EP3-recept0rs present (Smith et al, 1998). 
EP3-recept0rs are negatively coupled to adenylate cyclase via Gi and therefore 
cause a reduction in cyclic AMP production following stimulation of the receptor. This 
reduction in cyclic AMP production is believed to be the mechanism by which gastric 
acid secretion and neurotransmitter release are inhibited, but contraction of smooth 
muscle by stimulation ofthe EP3-recept0r is more likely to be due to Ca�+ mobilisation in 
these tissues (Coleman et al, 1987). This could perhaps be explained by the four EP3-
receptor isoforms identified from bovine adrenal gland cDNA and designated EP3A, EP3B, 
EP3c and EP3D when expressed in CHO cells O^amba et al, 1993). The EP3-recept0r 
splice variants EP3A and EP3c have been shown to couple to Gj and produce inhibition of 
adenylate cyclase, whilst EP3B positively couples to adenylate cyclase via Gs. 
Interestingly EP3D couples to Gq, in addition to G： and Gs, to produce inositol phosphate 
turnover and Ca�+ mobilisation. Although the tissue distribution of each isoform is not 
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known, selective distribution could explain the various actions mediated by EP3-recept0rs 
(Coleman et al., 1994a). Similar isoforms have also been identified in mice (Irie et al, 
1994) and homologous splice variants found in human and rabbit mRNA (Breyer et al., 
1993; Adam et al, 1994). 
1.3.5 EP4-recept0rs 
The EP4-recept0r is the most recently identified of the EP-receptors and was identified 
for the first time by Coleman et al (1994b) in pig saphenous vein. There is currently little 
information regarding the distribution of EP4-recept0rs although there are some 
suggestions that EP4-recept0rs may be present in rabbitjugular vein and saphenous vein, 
rat trachea, hamster uterus and rat neutrophils (Lawrence et al, 1992; Coleman et al, 
1994a; Wise, 1998). In situ hybridisation studies have recently identified EP4-recept0r 
mRNA present in uterus (Katsuyama et al, 1997), intestinal mucosa (Ding et al, 1997) 
kidney (Breyer et al” 1996) and nuclear envelope (Bhattacharya et al., 1999) of various 
species. Also EP4-recept0r mRNA has been detected in mouse DRG neurones (Oida et 
al, 1995) and more recently Nantel et al (1999，personal communication) have detected 
an abundance 0fEP4-recept0r mRNA in slices of rat DRG. 
The EP4-recept0r is positively coupled to adenylate cyclase via Gs, and shares 
many characteristics with the EP2-recept0r including smooth muscle relaxation (Lydford 
& McKechnie, 1994). The agonists that act on EP2-recept0rs are also active on EP4-
receptors, except for the selective EP2-recept0r agonist butaprost (Milne et al., 1994). In 
fact, previous to the identification of the EP4-recept0r by Coleman et al (1994b)，a 
number of cloned EP4-recept0rs had already been discovered in mouse (Honda et al., 
1993)，rat (Sando et al, 1994) and human cDNA libraries (Bastien et al, 1994)，but had 
been wrongly identified as EP2-recept0rs due to their ability to stimulate adenylate 
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cyclase. The fact that the mouse receptor did not respond to butaprost was initially 
attributed to species difference or the existence of an additional EP2-like receptor. 
However, when rat and human cloned receptors also had weak responses to butaprost, 
serious doubt was cast over the true identity of the cloned receptor (Pierce et al, 1995). It 
was not until Regan et al. (1994) cloned the fourth type of EP-receptor that had binding 
activity to butaprost, that researchers realised that this was the EP2-recept0r. Nishigaki et 
al. (1995) later confirmed that the previously cloned 'EP2-recept0r' was in fact the EP4-
receptor reported by Coleman et al (1994b)，and showed that the cloned EP4-recept0r did 
not respond to butaprost, but was selectively antagonised by the EP4 competitive 
antagonist AH23848B. 
1.3.6 FP-receptors 
FP-receptors are found in a variety of different tissues but they are by far the most 
prevalent is the corpus luteum, where they mediate luteolysis. Another tissue where FP-
receptor populations are significant is the iris sphincter muscle from cats and dogs, where 
FP-receptors mediate contraction (Coleman et al, 1994a). Indeed, since the iris sphincter 
muscle of cats and dog contain homogenous populations ofFP-receptors, the majority of 
FP-receptor characterisation has been carried out on this tissue (Coleman et al, 1994a). 
The FP-receptor probably mediates its contractile response via the PLC pathway, 
resulting in stimulation of inositol phosphate production and release of Ca:+ from internal 
stores OSfakao et al, 1993). Coupling ofthe FP-receptor to Gq has been confirmed in FP-
receptor cDNA-transfected CHO cells, where a Gqa antibody blocks responses to PGF2a 
(Ito et al, 1994). To date there has been no studies to investigate ifDRG cells posses any 
FP-receptor mRNA although recent investigations have demonstrated that stimulation of 
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rat DRG cells with PGF2a caused negligible effects on inositol phosphate and cyclic 
AMP levels (Smith et al, 1998). 
l 3 . 7 IP-receptors 
Prostacyclin receptors are traditionally found in platelets and smooth muscle where they 
mediate inhibition of aggregation and cause relaxation, respectively (Moncada, 1982). In 
situ hybridisation studies have demonstrated the presence of IP-receptor mRNA in the 
thymus, spleen and DRG of mice (Oida et al, 1995). There is a relative lack of [^ ；-
iloprost binding in the CNS, although high affinity binding sites have been detected in rat 
nucleus tractus solitarius Q^TS), spinal trigeminal nerve, dorsal horn and DRG 
(Matsumura et al., 1995). In contrast to the lack of [^]-iloprost binding sites in the CNS, 
an alternative IP-receptor radioligand [^]-isocarbacyclin binds well in rat thalamus, 
hippocampus, cerebral cortex, and NTS (Takechi et al, 1996). Furthermore, Takechi et 
al. (1996) identified 15R-16-m-tolyl isocarbacyclin as a highly selective agonist for this 
IP-receptor in the CNS, providing further evidence for a distinct subtype of IP-receptor 
present in the CNS. However, to date only the classical platelet type IP-receptor has been 
cloned from bovine (Hasse et al, 1997)，human (Katsuyama et al., 1994), mouse (Namba 
et al., 1994), and rat (Sasaki et al., 1994) cDNA libraries, therefore conformation of the 
proposed receptor subtype and naming of the novel receptor awaits its cloning. 
The classical IP-receptor found in platelets, smooth muscle and DRG cells, is 
known to positively couple to adenylate cyclase via Gs C^amba et al., 1994). Subsequent 
elevation of cyclic AMP is believed to account for the majority of the biological actions 
mediated by this receptor (Coleman et al, 1994a). The IP-receptor is also known to 
couple to Gq, as was demonstrated for the first time by Namba et al (1994) in mouse IP-
receptor transfected CHO cells; iloprost was shown to cause both an increase in cyclic 
8 
AMP and inositol phosphates (Fig. 1). The iloprost-stimulated cyclic AMP response was 
sensitive to cholera toxin, demonstrating the involvement to Gs, whilst cholera toxin had 
no effect on inositol phosphate production. 
�- Subsequent treatment with pertussis toxin showed that the inositol phosphate 
response was not dependent on Gi, therefore showing that the IP-receptor was able to 
couple to both Gs and Gq GS[amba et al., 1994). Recently, IP-receptor mediated responses 
have been investigated in adult rat DRG cells (Smith et al, 1998), and demonstrated that 
prostacyclin mimetics cicaprost and carbacyclin also caused increases in cyclic AMP and 



















































































































































































































































































































































As with IP-receptors, TP-receptors are widely distributed in vascular smooth muscle and 
platelets. In many respects the TP-receptor is the counterpart of the IP-receptor since as 
opposed to relaxing smooth muscle and inhibiting platelet aggregation, TP-receptors 
cause vasoconstriction and platelet aggregation. However, this is where the distribution 
similarities been these two receptors end, since TP-receptors have not been found in DRG 
cells and also unlike IP-receptors, TP-receptors are found in airway smooth muscles. TP-
receptors mediate their responses largely via Gq leading to PLC activation and inositol 
phosphate-dependent Ca�+ mobilisation (Coleman et al, 1994a). 
1.4 Agonists and antagonists 
Prostanoid receptor characterisation is based on the effects of specific agonists (rank 
order ofagonist potency) and antagonists (ability of the antagonist to block the response). 
However, due to the lack of a suitable range of specific receptor antagonists, prostanoid 
receptor classification tends also to rely on ligand binding studies (Coleman et al, 1984). 
For this current study, a number of prostanoid receptor agonists have been used in the 
characterisation of the IP-receptor on adult rat DRG cells, and are therefore described 
below (Fig. 2). 
Prostacyclin itself is a very potent IP-receptor agonist but unfortunately is 
chemically unstable and therefore has too short a duration of action for functional studies. 
More stable PGI2 analogues such as carbacyclin have been produced but increased 
stability was gained at the expense of potency (Coleman et al, 1994a). It was not until 
Schering produced iloprost that chemical stability and high IP-receptor potency was 
achieved (Coleman et al, 1994a). Iloprost has similar potency at the IP-receptor to PGI2， 
11 
but also possesses potent partial agonist activity on the EPi-receptor (Dong et al, 1986). 
Schering also produced cicaprost, which is slightly more potent than iloprost and is 
highly selective to the IP-receptor (Coleman et al, 1994a). Other agonists that act on the 
IP-receptor include PGEi which is a mixed EP/IP-receptor agonist (Katsuyama et al., 
1994; Namba et al, 1994) and BMY 45778 which has exhibited potent IP-receptor 
partial agonist activity on platelets (Seiler et al, 1997) and neutrophils (Wise et al, 
1995). 
PGE2 is an EP-receptor agonist, and can activate all four receptor subtypes with 
equal potency (Coleman et al, 1987)，as can PGE! the mixed EP/IP-receptor agonist with 
the exception ofthe EPi-receptor where its potency is 10-fold less than PGE2 at the same 
receptor (Coleman et al, 1994a). Sulprostone is a potent EP3-recept0r agonist although it 
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Figure 2. Chemical structures of prostacyclin, cicaprost, BMY 45778 and PGE2. 
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CHAPTER 2 
The role of prostacyclin in pain modulation 
•� 
2.1 Pain 
Pain is caused when tissue comes into contact with noxious stimuli, e.g. mechanical, 
chemical or thermal injury. Noxious stimuli cause the release of chemical mediators 
which can either act directly on the nociceptive terminals of primary sensory neurones to 
cause nociception, or enhance the neuronal response to other painful stimuli and reduce 
the pain threshold and thus cause hyperalgesia. Under normal physiological conditions, 
high-intensity stimulation of the primary afferent terminal causes stimulation of C-fibres 
of sensory neurones, whilst stimulation of A5-fibres that detect low-intensity stimulation 
(e.g. touch and pressure) causes no pain (Dray et al, 1994). However, following tissue 
damage and subsequent sensitisation of the primary sensory nerve fibres, C-fibre 
stimulation causes hyperalgesia whilst A5-fibre stimulation causes allodynia (a state of 
discomfort and pain evoked by innocuous tactile stimuli) (Dray et al, 1994). Both 
nociception and hyperalgesia lead to the release of neuropeptides and excitatory amino 
acids from the primary afferent terminals in the dorsal hom of the spinal cord, which 
facilitates the passage of the nociceptive or hyperalgesic signals from the spinal cord to 
the thalamus of the brain (Levine et al, 1993). 
One of the chemical mediators that are released from sites of tissue damage is 
bradykinin (Dray & Perkins，1993). Bradykinin stimulates two subtypes of receptor, B i 
and B2; the B2-recept0r dominates under normal conditions, whereas the Bi-receptor is 
upregulated under inflammatory conditions (Dray et al, 1994; Cesare & McNaughton, 
1997). Stimulation of both Bi and B2-recept0rs causes activation of PLC, which leads to 
14 
the production of inositol phosphates, DAG, and the elevation of [Ca^^]i. The resulting 
elevation of [Ca^^]i and activation ofPKC (Burgess et al, 1989; Cesare & McNaughton., 
1997) leads to either direct release of neuropeptides (Barber & Vasko, 1996)，or to the 
production of prostaglandins (Gammon et al, 1989) which then sensitise further 
responses causing hyperalgesia (Dray & Perkins, 1993). 
2.2 Prostaglandins and pain 
Prostaglandins have long been thought to contribute to painful stimuli (Kindgen-Miles, 
1995). Animal models of pain have demonstrated that prostaglandins, especially PGE2 
and PGI2, can sensitise subsequent responses to painful stimuli, very often with IP-
receptor agonists having a 10-fold greater potency than PGE2 in causing a painful 
response, as demonstrated in mouse writhing tests (Collier & Schneider 1972). Zymosan-
induced writhing in mice also produced PGI2 (measured as 6-keto-PGFia) and PGE2, 
again with PGI2 showing dominance (Doherty et al, 1987). In vitro studies have also 
shown that sensitisation of primary afferent terminals by PGI2 and PGE2 leads to 
increased release of neuropeptides such as substance P and calcitonin gene-related 
peptide (CGRP) when stimulated with bradykinin (Vasko et al., 1993; Hingtgen & 
Vasko, 1994; Vasko et al., 1994). The mechanism of the hyperalgesic response of 
prostaglandins that causes enhancement of bradykinin's response is still unclear, although 
it is known to be cyclic AMP-dependent, since stimulation of adenylate cyclase by 
forskolin also produces a similar response (Hingtgen et al, 1995). 
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2.3 Prostacyclin and pain 
Despite PGI2 having a more potent hyperalgesic activity than PGE2 in several of the 
above studies, until very recently it is PGE2 that has been considered as the major 
prostanoid involved in inflammatory pain (Vane, 1997). This is probably due to the fact 
that PGE2 was commercially available many years before PGI2, and also since PGE2 is 
much more stable than PGI2 (Smith et al, 1998). However, high concentrations of the 
prostacyclin metabolite 6-keto-PGFia are consistently found in inflammatory exudates, 
suggesting that prostacyclin is synthesised and released in areas of inflammation (Higgs 
& Salmon” 1979; Brodie et al, 1980; Bombardieri et al, 1981). In addition to this, over 
recent years, evidence has emerged that overwhelmingly suggests that PGI2 is the major 
prostanoid involved in inflammatory pain. The evidence includes: the presence of [ ^ ] -
iloprost binding sites in the central terminals of primary sensory neurones (Matsumura et 
al, 1995); high density presence of IP-receptor mRNA in DRG cells (Oida et al, 1995) 
and inflammatory pain responses in IP-receptor knockout mice reduced to levels seen in 
indomethacin-treated mice (Murata et al, 1997). There is also some evidence that PGI2 
may cause a direct nociceptive action of its own based on increases in neuropeptide 
release caused by prostacyclin mimetics (Hingtgen & Vasko, 1994). 
2.3.1 [3jj]-Iloprost binding sites 
Matsumura et al (1995) performed quantitative in vitro autoradiographic mapping ofIP-
receptors in the rat brain and spinal cord. They found the regions with the highest density 
of specific binding sites for [^]-iloprost G^TS, area postrema and the dorsal hom ofthe 
spinal cord), corresponded with the regions that contained the primary afferent fibre 
terminals. To determine whether or not these binding sites were on the presynaptic or 
postsynaptic side of the primary sensory neurone terminals, the nodose ganglion was 
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removed to destroy vagal innervation of the NTS. This resulted in a significantly reduced 
number of [^]-iloprost binding sites in the NTS, suggesting that the binding sites were 
indeed located presynaptically. This result was further supported by ligation of the vagus 
nerve, which demonstrated that [^]-iloprost binding sites were transported to the NTS 
from the nodose ganglion. Furthermore, dorsal rhizotomy of the DRG resulted in the loss 
of [^]-iloprost binding sites in the dorsal hom again supporting the hypothesis that the 
iloprost binding sites are transported from the cell body ofthe DRG. 
2.3.2 IP-receptor mRNA 
As mentioned previously in chapter 1，when using in situ hybridisation techniques, IP-
receptor mRNA has been found in mouse DRG neurones (Oida et al, 1995). It was 
reported that IP-receptor mRNA was found in approximately 40% of the neurones (small-
and large-sized) contained in the DRG. About 30% of the neurones contained the mRNA 
for the substance P precursor, PPTA, 70% of which also co-expressed IP-receptor 
mRNA. Approximately 21% of all neurones in the DRG therefore have the ability to 
produce substance P and respond to PGI2. Only 20 - 40% of the IP-receptor mRNA-
containing neurones co-expressed EP!，EP3 and EP4-recept0r mRNA (EP2-recept0r 
mRNA was not examined in this study). 
2.3.3 IP-receptor knockout mice 
By far the most striking evidence that PGI2 is the major prostanoid involved in 
inflammatory pain came with the IP-receptor knockout mice of Murata et al (1997). By 
using homologous recombination, the gene for the mouse IP-receptor was disrupted, thus 
producing IP-receptor-deficient mice that were viable, reproductive and normotensive. 
Acetic acid-induced writhing responses were compared between wild-type and IP-
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receptor knockout mice treated with the COX inhibitor indomethacin. The results 
demonstrated that the number of writhing responses in the IP-receptor knockout mice 
were reduced to the level of indomethacin-treated wild-type mice, thus implicating IP-
reCeptor-mediated responses with nociception. Under these conditions, acetic acid 
injection produced similar amounts of 6-keto-PGFia in wild-type and IP-receptor 
knockout mice. PGE2 was also produced but only to one quarter ofthe amount of 6-keto-
PGFia, demonstrating that the reduced responses were not due to lower prostanoid 
production in the IP-receptor knockout mice. In order to compare responses of PGI2 and 
PGE2, both prostaglandins were injected intraperitoneally into these animals. PGI2 
produced writhing responses in 60% of the wild-type mice and no responses in the IP-
receptor knockout mice, whereas PGE2 only induced writhing responses in 25% of both 
sets of mice. 
2.3.4 Direct nociceptive action of prostacyclin 
The first suggestion of a possible direct nociceptive action of PGI2 came when Geppetti 
et al. (1991) showed that PGI2 caused the release of CGRP from isolated guinea pig 
heart. The response was blocked by capsaicin pretreatment, suggesting that the release of 
CGRP was from capsaicin-sensitive neurones. More recently, Hingtgen & Vasko (1994) 
demonstrated that PGI2 (100 nM) caused a 3-fold increase in substance P release above 
basal, and carbacyclin (10 - 1000 nM) produced a 3-fold increase in substance P and 
CGRP release above basal in embryonic rat DRG sensory neurones in vitro. The cyclic 
AMP mimetics forskolin and cholera toxin failed to cause neuropeptide release, despite 
being able to cause enhancement of bradykinin and capsaicin-mediated responses. Since 
the IP-receptor is able to couple to both adenylate cyclase via Gs and to PLC via Gq, it is 
therefore possible that the sensitising effects of prostacyclin is mediated via cyclic AMP, 
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whereas direct release ofneuropeptides by prostacyclin mimetics could be via an increase 
in [Ca^^i and the activation ofPKC. 
2.4 Treatment of prostanoid-induced pain 
Since prostanoids can clearly cause hyperalgesia and even possibly cause direct 
nociception as in the case of PGI2, they may provide a useful target for combating 
inflammatory pain. Most attempts at blocking prostanoid formation have targeted the 
COX activity of endoperoxide synthase. Non-steroidal anti-inflammatory drugs 
O^SAIDs) such as aspirin and indomethacin successfully inhibit COX activity, but have 
been shown to cause detrimental side effects such as gastric ulceration and kidney 
toxicity. However over recent years, two isoforms of COX have been identified and 
named COX-1 and COX-2 (Xie et aL, 1991). Inhibition of the COX-2 isoform is thought 
to be largely responsible for the anti-inflammatory actions of NSAIDs whilst COX-1 
inhibition is accredited with the unwanted side effects ofNSAID treatment (Vane et al., 
1998). However, recent reports suggest that the actions of the COX enzymes may not be 
as clear-cut as originally thought, and that the roles of COX-1 and COX-2 may well 
overlap (Wallace, 1999). COX-2 derived prostaglandins have been shown to also have a 
crucial role in the maintenance of the gastrointestinal mucosa, and COX-1 derived 
prostaglandins have been found to also contribute to inflammation. The blockade of 
COX-2 may well not provide anti-inflammatory effects comparable to non-selective 
COX inhibitors, and due to the high concentrations of COX-2 inhibitors needed to 
achieve the desired anti-inflammatory effects, COX-2 inhibitors may well be acting on 
COX-1 as well (Wallace, 1999). The potential ineffectiveness of COX-2 inhibitors leads 
to the search of new targets such as IP-receptor antagonists that could block possible 




neurones are believed to be the same as the classical platelet type IP-receptor, blocking of 
this receptor could lead to thrombosis as demonstrated in the IP-receptor knockout mice 








Dorsal root ganglion cells 
� 
3.1 In vitro model of pain 
Traditional models of pain have relied on live animal experimentation, using procedures 
such as the hot plate test, paw pressure test, tail flick test and the writhing test (Ferreira et 
aU 1978; Doherty et al, 1987; Hosoi et al, 1997; Murata et al, 1997). Despite the 
success of many of these techniques in determining the causes of nociception and 
hyperalgesia, the underlying biochemical mechanism of these responses cannot easily be 
measured in vivo. In addition, there is increasing concern amongst government and the 
general public that there is too much live animal experimentation and there may come a 
time when live animal testing may no longer be permitted. It is for these reasons that we 
have chosen to characterise prostacyclin receptor responses using an in vitro model. 
The vast heterogeneity ofboth neuronal and non-neuronal glial cells present in the 
nervous system has proved to be a major barrier in understanding the role of individual 
subclasses of neuronal cells (Lindsay et al, 1991). However, by isolating and enriching 
individual classes of neurones, their precise biochemical and physiological roles can be 
studied. As indicated in the previous chapter, primary afferent fibres of DRG neurones 
play a major role in transmitting and mediating signals of nociception and hyperalgesia. 
By isolating these neurones we hope to further clarify the role of prostacyclin in 
transmitting hyperalgesic and nociceptive signals and in effect use isolated adult rat DRG 
cells as an in vitro model ofpain. 
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3.2 Characteristics of cultured DRG cells 
3.2.1 Size and distribution 
DRG cells can be separated by size into two main populations; namely large diameter 
neurones and small diameter neurones (Lawson, 1979; Bowie et al, 1994; Gilabert & 
McNaughton 1997). Both sets of neurones are normally distributed in size and both 
distributions overlap (Lawson, 1979). The small diameter neurones vary in size from 7 
ixm to 33 i^m in cell body diameter, with the 21 ^m size being the most common. The 
large diameter neurones are between 15 i^m and 40 )im in cell body diameter with the 24 
^m diameter being the most common (Gilabert & McNaughton，1997). The large 
diameter neurones consist of fast-conducting myelinated axons called A-fibres，whose 
primary role is to detect mechanical stimuli (Dray et al, 1994). The small diameter 
neurones are comprised of slow conducting non-myelinated C-fibres, which are 
responsible for conducting nociceptive signals (Dray et al, 1994). Other morphological 
features of these neurones are that large diameter neurones posses large amounts of 
neurofilaments whereas small diameter neurones do not (Perry et al., 1991). 
3.2.2 Biochemical and physiological characteristics 
The roles of each separate group of DRG cells can be clearly defined not only due to the 
type of axonal fibres and morphological features, but also by their physiological action or 
biochemical content. 
22 
3.2.2.1 Capsaicin-sensitive neurones 
Capsaicin sensitivity has long been associated with nociceptive neurones. In order to 
distinguish between nociceptive and non-nociceptive neurones, neonatal DRG cells can 
be pretreated with capsaicin by administering capsaicin to their mothers. This results in 
the capsaicin-sensitive neurones being destroyed (Winter, 1987). Unfortunately, even 
high doses of capsaicin administered to adult rats failed to cause the large-scale 
destruction of small diameter neurones seen with neonatal administration (Jancso et al, 
1985). This problem ofidentifying capsaicin-sensitive neurones was resolved in adult rats 
by using a cobalt uptake assay. Since cobalt uptake is capsaicin-dependent, levels of 
cobalt can be used to distinguish between capsaicin-sensitive and insensitive neurones in 
adult DRG. In fact, Winter (1987) demonstrated that only small diameter neurones were 
capsaicin-sensitive, therefore indicating that small diameter neurones were nociceptive. 
3.2.2.2 Neuropeptide content 
Since the release ofneuropeptides such as substance P and CGRP are clearly involved in 
nociceptive and hyperalgesic responses, the presence of these neuropeptides in neurones 
can indicate nociceptive characteristics. Substance P and CGRP immunoreactivity studies 
in neonatal rat DRG cells have demonstrated that small diameter capsaicin-sensitive 
neurones possess significantly more of both neuropeptides than large diameter DRG cells 
(Bowie et al., 1994; Gilabert & McNaughton, 1997). Subsequent substance P-like 
immunoreactivity studies on adult guinea pig DRG neurones also demonstrated that there 
is a tendency for neurones with small cell bodies and slow conduction velocities to 
contain substance P (Lawson et al, 1997). 
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3,2.13 Elevation of[Ca^^]i 
The ability of a variety of receptor agonists to increase the concentration of intracellular 
Ca2+ can also help distinguish between different DRG neuronal cell populations. 
Stimulation ofneonatal rat DRG neurones with capsaicin and bradykinin elevated resting 
levels of [Ca^^i in small diameter neurones, whilst the large diameter neurones were 
unresponsive. Capsaicin evoked a biphasic response, which rose to a peak and was 
followed by a long-lasting plateau component (Bowie et al, 1994). 
3.3 Effect of nerve growth factor 
The role of nerve growth factor fNGF) in the development of the peripheral nervous 
system is now well documented, and demonstrates that the majority ofDRG neurones are 
absolutely dependent on NGF during embryogenesis and early postnatal life (Lindsay, 
1988). However, Lindsay (1988) demonstrated that NGF, although being able to enhance 
axonal regeneration, was not required for survival of adult rat DRG cells. Despite this, 
later studies demonstrated that although substance P and CGRP levels could be detected 
in adult rat DRG cells after 2 days in culture using immunofluorescent staining, longer 
cultures of up to 14 days showed significant reduction in both neuropeptide levels. 
Quantification by radio-immunoassay of substance P and CGRP levels confirmed that the 
presence ofNGF produced 10 - 15 fold higher levels of substance P and CGRP (Lindsay 
et al, 1989). 
The addition ofNGF to cultures of rat DRG cells has also been shown to increase 
responses to nociceptive mediators such as bradykinin. Intracellular recordings of small 
diameter adult rat DRG neurones demonstrated that depolarisation of the neurones by 
bradykinin was observed in 46% of the neurones grown in the presence ofNGF, whereas 
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only 11% of the neurones with no NGF exposure responded (Kasai et al, 1998). This 
indicates thatNGF may play a role in regulation ofbradykinin receptor expression. 
Nerve growth factor has also been implicated as an important chemical link 
between tissue injury and changes in sensory neurone function that can lead to pain 
(Lewin & Barde，1996). Blockade ofNGF activity with antibodies prevents both heat and 
mechanical hyperalgesia, which normally follows tissue inflammation (Woolf et al, 
1994). It appears that the role of NGF is to increase the synaptic efficacy of sensory 
neurone connections in the spinal cord, which in part mediates the hyperalgesia. This is 
supported by the fact that administration of NGF causes hyperalgesia in animals and 
humans (Lewin et al, 1993； Lewin & Barde，1996). 
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CHAPTER 4 
Materials and solutions 
� 
4.1 Materials 
Aqueous solutions were prepared in ultra-pure H2O (i.e. double distilled, deionised 
water). 
8-[^H]-adenine (specific activity 27 Ci/mmol) was purchased from Amersham and stored 
at 4�C. 
Acetic Acid (glacial 100%, Merck) 
Alumina (neutral alumina, Sigma) 
Ammonium formate (Sigma) 
Ammonia solution (25%, BDH) 
ATP (adenosine 5'-triphosphate, Sigma) was prepared fresh on day ofassay. 
Bacitracin (Sigma) was dissolved in modified HEPES buffer on the day of experiment. 
BMY 45778 (a gift from Bristol-Myers-Squibb, USA) was reconstituted at 10 mM in 
DMSO and stored at -20°C. 
Bovine serum albumin (Sigma) 
Bovine serum albumin, essentially fatty acid free (Sigma) was prepared in incomplete 
F14 medium (15%, w/v), and filter sterilised on the day of experiment. 
Bradykinin (Sigma) was prepared as a 10 mM stock solution in ultra-pure water. 
Capsaicin (Tocris) was dissolved in ethanol into a concentration of 10 mM. 
Calcitonin gene-related peptide (Sigma) 
CGRP EIA kit (Cayman) 
Cholera Toxin (Sigma) 
26 
Cicaprost (gift from Schering AG, Germany) was supplied in aqueous solution (137 pM) 
and stored at -20°C. 
Collagenase B (Roche Diagnostics) was prepared as a stock solution in incomplete F14 
medium (1.25%, v/v), filter sterilised, aliquoted and stored at -20°C. 
Cyclic AMP EIA kit (Cayman) 
Cytosine Arabinoside (Sigma) was prepared in incomplete F14 media to a final 
concentration of 0.1 M, filter sterilised, aliquoted, and stored at -20�C. 
DAB (3,3'-diaminobenzidine tetrahydrochloride, Sigma) 
Dimethyl Sulphoxide (Sigma) 
Dimethyl dichloro silane (Sigma) 
DNase (deoxyribonuclease I, Sigma) 
Dorminal (20% pentobarbital solution, Alfasan, Holland) was diluted with ultra-pure 
water prior to use to a concentration of 4%. 
Dowex (AG 50W-X4 resin, hydrogen form, 200-400 mesh, Bio-Rad) 
Dowex (AG l-X8 resin, formate form, 100-200 mesh, Bio-Rad) 
DPCPX (8-cyclopentyl-l,3-dipropylaxanthine, Sigma) 
Ethanol (Absolute, Merck) 
Formic acid (BDH) was prepared as a 1 M solution by diluting 37.73 ml of 26.5 M 
formic acid stock in 1000 ml ultra-pure H2O. 
Forskolin (Sigma) was dissolved in absolute ethanol at 10 mM and stored at -20�C. 
Fura-2-AM (fura-2 acetoxy methyl ester, Sigma) was dissolved in ultra-pure H2O at 1 
mM, aliquoted and stored at -20°C and protected from light. 
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HEPES (Sigma) 
Hydrochloric Acid (12.1 M, Merck) 
IBMX (3-isobutyl-l-methyl-xanthine, Sigma) was dissolved in DMSO at 100 mM and 
stoled at 4�C. 
Iloprost (gift from Schering AG, Germany) was dissolved in ultra-pure H2O to a final 
concentration of 1 mM and stored at -20°C. 
Indomethacin (Sigma) was dissolved in absolute ethanol at 10 mM and stored at -20°C. 
Laminin (Gibco) stock of 1 mg/ml was diluted to 0.25 mg/ml with sterile PBSA, filter 
sterilised, aliquoted and stored at -20°C. 
L-Glutamine (Gibco) was prepared as a 200 mM solution with incomplete F14 media, 
filter sterilised, aliquoted and stored at -20°C. 
Lithium Chloride (Sigma) was prepared as a 1 M solution in incomplete DMEM 
medium and diluted in assay buffer to a final concentration of20 mM. 
Methanol (Merck) 
Myo-inositol - [ 2 -¾ (N)] (specific activity 22.2 Ci/mmol) was purchased from NEN and 
stored at 4°C. 
Naltrexone (Sigma) 
NECA (5'-N-Ethylcarboxaminoadenosine, Sigma) 
NGF (nerve growth factor, mouse 2.5s，Alomone Labs., Israel) was reconstituted with 
incomplete F14 media to a concentration of 10 n,g/ml, filter sterilised, aliquoted and 
stored at -70°C for up to six weeks. 
Paraformaldehyde (Sigma) was diluted in PBS to a final concentration of 4% (w/v). 
Penicillin/Streptomycin solution (Sigma) was reconstituted with 20 ml sterile ultra-pure 
H2O and stored at 4°C. 
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Pertussis toxin (Sigma) was supplied at a concentration of 50 pgAnl in a 50% glycerol 
solution containing 50 mM Tris, 10 mM glycine and 0.5 M NaCl and was stored at -
20�C. 
Pr^taglandin Ei (Sigma) was dissolved in absolute ethanol to a concentration of 10 
mM, and stored at -20°C. 
Prostaglandin E2 (Sigma) was dissolved in absolute ethanol to a concentration of 10 
mM, and stored at -20°C. 
PMA ^)horbol 12-myristate 13-acetate, Sigma) was dissolved in DMSO at 1 mg/ml and 
stored in small aliquots at -20�C. 
Poly-DL-Ornithine (hydrobromide salt, Sigma) was made up to a concentration of 25 
mg/ml in ultra-pure H2O, filter sterilised, aliquoted and stored at -20°C. 
Rabbit Anti-Glial Protein (GFAP) (DAKO) Purchased diluted. 
Rabbit Anti-Human Myelin Basic Protein (MBP) (DAKO) Purchased diluted. 
Rabbit Anti-Neurone Specific Enolase (NSE) (DAKO) Purchased diluted. 
Substance P (Sigma) 
Substance P EIA kit (Cayman) 
Sulprostone (Schering AG, Germany) was dissolved in absolute ethanol at 5 mg/ml 
(10.7 mM) and stored at -20°C. 
Trichloroacetic acid (Sigma) was dissolved in ultra-pure H2O to a concentration of 10% 
(w/v) and stored at 4°C. 
Trypsin (Roche Diagnostics) was prepared as a 2.5% (w/v) stock solution in PBSA, filter 
sterilised, and stored at -20°C. 
Trypsin Inhibitor (Soybean, Sigma) 
Ultroser G (Gibco) was reconstituted with 20 ml sterile ultra-pure H2O and stored at 
4�C. 
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Vectastain ABC kit (biotinylated anti-rabbit IgG,) 
Xylene (BDH) 
Common laboratory reagents not listed (ACS grade) were purchased from Sigma. All 
disposable tissue culture dishes were supplied by Nunc. Sprague-Dawley rats were 
supplied by the Laboratory Animal Service Centre (LASEC). 
4.2 Culture media, buffers and solutions 
4.2.1 Culture media 
DMEM (inositol free, Gibco). Penicillin (100 units/ml) and streptomycin (100 i^gAnl) 
was added to each 500 ml bottle of DMEM to form incomplete medium, and stored at 
40C. Immediately prior to the experiment, the artificial serum substitute ultraser G (4%, 
v/v) and L-glutamine (2 mM) were added to form complete media. 
Ham's Nutrient Mixture F14 (Imperial Laboratories) was reconstituted with 5000 ml 
ultra-pure H2O, and supplemented with NaHCO3 (1.176 g/L). The pH was adjusted to 7.6 
with 6 M NaOH and filter sterilised through a 0.22 i^m filter into 1000 ml bottles to give 
a fmal pH of 7.4. Penicillin (100 units/ml) and streptomycin (100 M-g/ml) was added to 
each 1000 ml bottle to form incomplete medium, and stored at 4�C. Immediately prior to 
the experiment, the artificial serum substitute ultraser G (4%, v/v) and L-glutamine (2 
mM) were added to form complete media. 
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4.2.2 Buffers 
Dulbecco's PBS (PBSA: Ca^VMg^^ free) was prepared with the following ACS reagents 
supplied by Sigma: KC1 (2.7 mM)，KH2PO4 (1.4 mM), NaCl (137 mM) and Na2HPO4 
(g:l mM) in ultra-pure H2O. The pH was adjusted to 7.5 and the solution was filter 
sterilised giving a final pH of7.4. 
Modified HEPES buffer was prepared with the following ACS reagents supplied by 
Sigma: HEPES (25 mM), NaCl (135 mM), KC1 (3.5 mM), CaCl2 (2.5 mM), MgCl2 (1 
mM) and glucose (3.3 mM) in ultra-pure H2O, pH 7.4. 
Phosphate Buffered Saline (PBS) was prepared with the following ACS reagents 
supplied by Sigma: Na2HPO4 (8.3 mM), NaCl (136 mM), KC1 (2.7 mM), KH2PO4 (1.5 
mM) in ultra-pure H2O, pH 7.4. 
Tris-Buffered Saline (TBS) was prepared using Tris-HCl (50 mM) and NaCl (6.4 mM) 
in ultra-pure H2O. The pH was adjusted to 7.6 with 6 M HC1. 
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4.2.3 Solutions 
DAB solution was prepared by dissolving DAB (0.5 mg/ml) in TBS and adding 
hydrogen peroxide to a final concentration ofO.015% (v/v). 
� 
DNase (Deoxyribonuclease I) plus Trypsin Inhibitor Solution was prepared by 
dissolving DNase (0.04%, w/v), Soybean trypsin inhibitor (0.05%, w/v) and 
MgSO4.7H2O (2.31%, w/v) in incomplete F14 medium. The solution was then filter 
sterilised, aliquoted and stored at -20°C. 
Imidazole (0.5 M) was prepared by dissolving 52.25 gyL imidazole (Sigma) with ultra-
pure H2O and the pH adjusted to 7.5 with NaOH. This stock solution was diluted to 0.1 
M with ultra-pure H2O before use. 
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CHAPTER 5 
Development of dorsal root ganglion cell preparation 
-� 
5.1 Introduction 
It is now over 20 years since Scott (1977) first described the establishment of dissociated 
cultures of adult DRG cells. However, it was not until 1991 that Lindsay et al. (1991) 
developed a method that had sufficient yield and purity to perform accurate studies of 
DRG cell development and function. It is on this latter technique that we have based our 
preparation. Briefly, the method involves treatment of the isolated dorsal root ganglia 
with enzymes such as collagenase and trypsin followed by mechanical dissociation with a 
Pasteur pipette to produce a single cell suspension. The neuronal cells can then be 
enriched using either a BSA gradient (Acs et al., 1996) or differential adhesion (Lindsay 
et al., 1991). The dissociated cells are cultured in the presence ofNGF which, although 
not essential for growth of isolated adult sensory neurones (Lindsay, 1988), was included 
since it is has been shown to increase neuropeptide stores (Lindsay et al., 1989)，and the 
expression ofbradykinin receptors (Kasai et al, 1998). Cytosine arabinoside (Ara C) was 
included since it is a mitotic inhibitor, thus preventing the proliferation of any 
contaminating non-neuronal cells. The aims of the following experiments were to 
determine which combination of these techniques gave the maximum neuronal cell yield, 
viability and purity. 
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5.2 Methods 
5.2.1 Dissection of dorsal root ganglia 
Male Sprague Dawley rats (150 g - 200 g) were anaesthetised with pentobarbitone (40 
mg/kg, i.p.) and their spinal columns removed using aseptic techniques. Each removed 
spine was then wrapped in aluminium foil and placed in ice prior to removal of excess 
tissue surrounding the spine. Detachment of the dorsal half of the vertebrae was achieved 
by cutting a strip ofbone along the whole length of the spine, with Malleus Nippers, thus 
exposing the spinal cord. Dorsal root ganglia were then removed from all regions ofthe 
spinal cord by gently displacing the spinal cord a few millimetres to the side, 
consequently exposing the DRG from their recessed bony cavities. The DRG could be 
easily identified as pronounced swellings on the white nerve trunk. Once removed using 
small spring scissors and watchmaker's forceps, the DRG were placed in 2 ml ofF14 
complete medium. With practice, approximately 40 DRG could be removed from each 
rat. 
5.2.2 Preparation of a single-cell suspension 
In order to prepare isolated DRG cells, the ganglion must first be cleared of connective 
tissue before enzymatic treatment. The effect of trimming the DRG and the effects of 
different concentrations and combinations of enzymes was investigated. 
5.2.2.1 Effect oftrimming dorsal root ganglia 
With the aid of a dissecting microscope, half of the ganglia were trimmed with a scalpel 
so as to remove any remaining nerve trunks, and the remaining ganglia left untrimmed. 
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The cell yields from these preparations were then compared following enzymatic 
treatment and mechanical dissociation. 
5,2,2.2 Enzymatic dissociation 
(a) Effect of collagenase alone. 
The DRG were transferred into fresh F14 complete medium, and incubated with 
collagenase B. Since different batches of collagenase vary in specific activity, various 
concentrations of collagenase (0.125% - 0.25%) and different incubation times (1.5 h x 2 
and 3 h) were tested. The DRG were then transferred into 15 ml conical tissue culture 
tubes and washed twice in F14 complete medium (5 min, 43 x g, 20°C), and the 
supernatant discarded. The DRG were then resuspended in 2 ml F14 complete medium, 
ready for mechanical dissociation. 
(b) Effect of collagenase plus trypsin. 
The effect of combining the collagenase treatment with trypsin treatment, followed by 
DNase/trypsin inhibitor solution was also investigated. In this case, following collagenase 
(0.125%) treatment, the ganglia were transferred into 15 ml conical tissue culture tubes 
and washed twice with F14 incomplete medium. The cells were then incubated with 
trypsin (0.25%) for 30 min at 37°C, followed by addition of 10 ml F14 complete medium. 
The ganglia were then centrifuged (5 min, 43 x g，20°C) and the F14 complete medium 
removed. The DRG were then resuspended in 2 ml of DNase (0.04%, w/v) and soybean 
trypsin inhibitor (0.05%, w/v) solution, in preparation for mechanical dissociation. 
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5.2,2.3 Mechanical dissociation 
Following enzymatic treatment, the DRG were passed through flame polished salinized 
Pasteur pipettes in order to form a single cell suspension. The number of triturations 
needed to form a cloudy cell suspension was dependent on how well the enzymes had 
digested the connective tissue in the previous preparative steps. The number of 
triturations was kept to a minimum (usually 6 - 8) as excessive mechanical force leads to 
low cell yields. 
5.2.3 Neuronal cell enrichment 
In order to prepare a pure neuronal cell preparation, any non-neuronal cells present in the 
dissociated cell suspension must be removed. The enrichment techniques attempted were 
differential adhesion (Lindsay et al, 1991)，BSA gradient (Acs et al, 1996) and a 
combination of both. The aim being to determine which method gave greatest neuronal 
cell enrichment without sacrificing neuronal cell yield and viability. To determine the 
most efficient technique, the cells were observed after 5 days in culture and the number 
of each cell type in a randomly selected area of 1 mm^ was counted (i.e. approximately 
900 cells/condition). Cell types were determined morphologically. 
5.2.3.1 Differential adhesion 
The dissociated cell suspension from each rat was divided into two and plated into poly-
DL-omithine-coated 60 mm tissue culture dishes. After 16 - 18 h，the non-neuronal cells 
should be firmly attached to the culture dish, the neurones lightly attached to the dish, 
whilst the myelin and cell debris are left in suspension. The medium containing myelin 
and cell debris was aspirated and discarded. Fresh F14 complete medium was then 
applied and the neurones recovered by gently dislodging from the dish using a stream of 
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medium from a Pasteur pipette. This process was repeated if neuronal cells still remained 
after the first wash. 
/ 
5,23,2BSAgradient 
The dissociated cell suspension from each rat was divided into two and placed into 15 ml 
conical tissue culture tubes. To these tubes an equal volume ofBSA (12 - 15%, w/v) was 
added underneath the cell suspension. The tubes were then centrifuged (96 x g, 10 min, 
20�C)，causing the neuronal cells to form a pellet and the myelin and cell debris to be 
trapped between the layers of BSA and medium. The pelleted cells were then removed 
using a salinized Pasteur pipette, washed (43 x g, 5 min, 20�C) in F14 complete medium 
and finally resuspended in the appropriate amount ofF14 complete for counting (see cell 
counting). 
5,2.3,3 Combination ofBSA gradient and differential adhesion 
A combination of both enrichment techniques was performed by first removing the 
myelin and cell debris using the BSA gradient, followed by the differential adhesion 
method to remove the non-neuronal cells. After neuronal cell enrichment, the cells were 
rinsed in F14 complete medium, centrifuged (43 x g，5 min, 20°C), and the supernatant 
discarded. The pellet was then resuspended in 500 i^l F14 complete medium and the cell 
yield counted. 
5.2.4 Cell counting 
The DRG cell yield, viability and purity was assessed by counting the number of cells 
using a Neubaur haemocytometer slide in the presence of trypan blue (0.4%, w/v). An 
aliquot ofthe DRG cell suspension was mixed with the dye in the ratio o f l : l , and 10 ^ il 
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of the dye-loaded cells were then added to the haemocytometer under a glass coverslip 
and observed using a phase contrast microscope. The neuronal DRG cells were identified 
as phase bright circular cells, whilst any remaining myelin and non-neuronal cells could 
be�identified as long fibrous cells and dark phase cells, respectively. Viable cells do not 
take up the dye, whilst dead cells are stained blue. The cell yield was determined by 
counting the viable DRG cells and calculated as follows: 
Number ofcells/ml = (average number of cells per 1 mm^) x 10^ x dilution factor. 
Where cell density values are given in the text as 15,000 cells/well, this represents 15,000 
phase bright circular (i.e. neuronal) cells. 
5.2.5 Culture conditions 
Prior to deciding on the final culture conditions, a number of experiments were 
performed to assess the effect of the mitotic inhibitor Ara C on non-neuronal cell growth 
and the effect of NGF on neuronal cell process formation. Briefly, DRG cells (2000 
cells/well, 24-well plate) were plated onto poly-DL-omithine/laminin-coated wells and 
cultured in 1 ml F14 complete medium at 37°C, 5% CO2 in a humidified atmosphere, in 
the presence and absence of Ara C (10 ^iM). After 5 days in culture, the numbers of 
neuronal and non-neuronal cells were assessed under each condition using phase contrast 
microscopy and also the effect of iloprost (10 p,M) and forskolin (10 \iM) on cyclic AMP 
production under each treatment was also examined. The effect of NGF on neuronal 
process formation was assessed by comparing DRG cells (2,000 cells/well, 24-well plate) 
grown in the presence of differing concentrations of NGF (0 - 100 ng/ml) and again 
assessed using phase contrast microscopy. 
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5.2.6 Size distribution of DRG cells 
A measuring reticule was placed in the eye piece of a phase contrast microscope and the 
size distribution of the DRG cells was determined by measuring the diameters of 200 
randomly-chosen DRG cells prepared using the BSA purification technique. 
5.2.7 Immunocytochemistry 
In order to confirm the identity of the cells present in the DRG cell preparation, 
immunocytochemical studies were performed. Cells (2000 cells/coverslip) were plated 
onto poly-DL-omithine/laminin-coated 13 mm glass coverslips, placed in 6-well plates 
and grown in F14 complete media containing NGF (50 ng/ml) and Ara C (10 ^iM). After 
5 days in culture, the cells were fixed onto the coverslips by immersing in 4% para-
formaldehyde (30 min), followed by washing with PBS buffer. The cells were then 
incubated with rabbit anti-primary antibodies specific either for neurones (neurone 
specific enolase, NSE), glial cells (GFAP) or myelin (myelin basic protein, MBP) for 60 
min at room temperature with their negative controls in parallel. The coverslips were then 
washed with PBS before incubation with the secondary antibody (biotinylated anti-rabbit 
IgG, Vectastain ABC kit) for 30 min at room temperature. Finally, again after rinsing 
with PBS, the cells were incubated with ABC complex reagent for 30 min at room 
temperature. 
In order to visualise the antibody, a conventional DAB reaction was used. Briefly， 
the coverslips were washed with TBS buffer and then covered with DAB. Once the 
brown colour started to emerge the reaction was stopped using tap water. The slides were 
then dehydrated in increasing concentrations of ethanol (70% - 100%) and cleared in 
xylene before mounting the coverslips onto microscope slides. 
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I 5.3 Results and discussion 
I ^ 
、 
5.3.1 Preparation of a single-cell suspension 
t 
tf . 
I Lindsay et al, (1991) suggested that each DRG should be individually trimmed of excess 
nerve trunks using a scalpel; the idea being that this would reduce the need of mechanical 
treatment and thus increase cell yield. In our experiments trimming had no apparent 
benefit on cell yield (see Table 1, Test 1)，but did improve purity since trimming reduced 
the amount of myelin in the preparation. However, subsequent experiments showed that 
i 
if care was taken when initially removing the DRG from the spinal cord, the majority of 
the nerve trunk could be removed at that stage, thus enabling us to avoid using the time-
-^
consuming DRG trimming technique. 
Enzymatic treatment of the DRG cells demonstrated that replacing the 
collagenase after 1.5 h with fresh collagenase did not improve cell yield (Table 1, Test 2). 
However, increasing the collagenase concentration from 0.125% to 0.25% (37�C，3 h) did 
markedly improve cell yield (Table 1，Test 3). Addition of trypsin (0.25%) following 
^ collagenase (0.125%) treatment, gave the highest yields and cell viability (Table 1，Test 
4). The increase in cell yield was probably due to better digestion of the connective 
tissues, since increasing the collagenase concentration and including the trypsin 
t. I 
I incubation step reduced the number of triturations needed, thus reducing the number of 
i 
J cells destroyed by the mechanical dissociation process (Table 1). The inclusion of 
^ DNase/trypsin inhibitor solution also probably contributed to the higher cell yield since 
- the DNase served to break down any DNA released from lysed cells therefore preventing 
1 ‘ 
i the cells from sticking together, whilst the trypsin inhibitor prevented any further 
I 



























































































































































































































































































5.3.2 Neuronal cell enrichment 
The effects of the different neuronal enrichment techniques on cell yield indicated that 
the cell yield was highest with BSA enrichment alone (62,000 cells/rat), compared to the 
differential adhesion procedure (53,000 cells/rat) or a combination of both treatments 
(26,000 cells/rat). The lower yields in the differential adhesion method and the 
combination method was probably due to the increased handling of the fragile DRG cells 
in these steps. 
The highest purity of DRG cells was obtained from the BSA enrichment 
technique (80%)，followed by the combination of BSA and differential adhesion (75%) 
and differential adhesion alone (50%) (Fig. 3). The differential adhesion method was very 
effective at removing astrocytes but was not very effective at removing myelin. The low 
cell purity in the differential adhesion method was again probably due to the DRG cells 
being destroyed during the process, which involved pipetting the cells through a Pasteur 
pipette a number of times. 
5.3.3 Size distribution of DRG cells 
The size distribution of 200 randomly chosen DRG cells showed the cells to vary in 
diameters between 15 p,m and 45 i^m. The most common size ofDRG cell was 25 i^m in 
diameter making up over 35% of the cell population (Fig. 4). The size distribution 
obtained was similar to that found by other workers (Winter, 1987; Bowie et al, 1994; 
Gilabert & McNaughton, 1997; Kasai et al, 1998). 
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Figure 4. Size distribution ofDRG cells prepared using the BSA purification method. 
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5.3.4 Effects of mitotic inhibitors and NGF 
In order to assess if the inclusion of Ara C in the tissue culture medium influenced non-
neuronal cell proliferation, DRG cells (2,000 cells/well, 24-well plate) were grown for 5 
days in the presence or absence of the mitotic inhibitor Ara C (10 ^iM). Initial studies 
attempting immunocytochemical staining under these conditions failed, therefore the 
experiment relied on morphological identification of different cell types using phase 
contrast microscopy (estimated from photographs containing approximately 750 cells). 
The results demonstrated, that despite the initial estimation of 80% purity of DRG cells 
following the BSA separation method (Fig. 3), the number of visible non-neuronal cells 
had increased dramatically despite the presence of Ara C after 5 days in culture. In the 
presence of Ara C non-neuronal cells comprised approximately 61% of the total cell 
population, whilst in the absence of Ara C were increased to 75% of the total cell 
population. Incubation of the cells with other mitotic inhibitors such as 5-
fluorodeoxyuridine (100 i^M) also had little effect on non-neuronal cell numbers. These 
results demonstrated that despite the presence of a mitotic inhibitors some non-neuronal 
cells still proliferate, albeit at a slower rate. The DRG cell yield in these experiments 
were double (124,000 cells/rat) those when the BSA separation method was evaluated, 
perhaps suggesting that increased cell yield may have been achieved at the expense of 
DRG cell purity. These results also stressed the need for immunocytochemical staining of 
the DRG cell preparation in order to identify the non-neuronal cells present (see section 
5.3.5). 
Mitotic inhibitors are routinely used in the study of DRG cells (Winter, 1987; 
Burgess et al, 1989; White, 1996; Smith et al, 1998), therefore Ara C was also included 
in all of our cell preparations. In order to assess the effect of Ara C on cellular responses, 
cyclic AMP assays (see section 6.2 for details) on DRG cells (15,000 cells/well) grown in 
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the presence or absence of Ara C were conducted. The results showed that the presence 
of the mitotic inhibitor increased responses to iloprost (10 i^M) (土 Ara C: 4.0 士 0.3 and 
2.4 土 0.04 fold basal) and forskolin (10 ^M) (土 Ara C: 59.6 土 3.2 and 34.4 士 2.3 fold 
basal), whereas basal cyclic AMP production decreased in the presence of Ara C (Basal 士 
Ara C: 1.88 土 0.09 and 3.08 士 0.36 cyclic AMP production, results are from one 
experiment performed in triplicate). Since the number ofDRG cells in this experiment is 
constant, then presumably the increased number of non-neuronal cells present in the 
absence of Ara C, are inhibiting the stimulated adenylate cyclase activity. The reduction 
of the iloprost response in the absence of Ara C may therefore suggest that the non-
neuronal cells present do not possess IP-receptors. Indeed previous work has found that 
iloprost failed to stimulate adenylate cyclase in astrocytes, despite a measurable response 
to PGEz (Ito et al, 1992). 
The presence of NGF has been shown not to be essential in adult rat DRG cell 
cultures although inclusion of NGF does improve neuropeptide content and neuronal 
process formation (Lindsay, 1988). Morphological studies were therefore conducted to 
assess differences in the presence and absence of NGF. The results indicated that 
increasing the concentration ofNGF from 0 - 100 ng/ml had no apparent effect on neurite 
outgrowth or any other morphological features of the DRG cells when viewed under 
phase contrast microscope. Under both conditions, DRG cells had already began to grow 
processes after 1 day in culture, and by day 5 the majority of the cell culture well was 
covered with neuronal processes (Fig. 5). 
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Figure 5. Phase contrast image ofDRG cell preparation after 5 days in culture. (A) 500 






Figure 5 shows typical phase contrast views of the DRQ cell preparation used in the 
current study. For Figure 6，I have used 2000 cells/coverslip to match the cell density 
us€d for the immunocytochemical studies, and extensive neurite outgrowth is clearly 
visible. 
Figures 7 and 8 demonstrate results of immunocytochemical staining of DRG cell 
preparations (2000 cells/coverslip) with NSE and GFAP after 5 days in culture. Myelin 
basic protein failed to stain any cells present in our preparation. Negative control staining 
for the NSE group stained the background light brown whilst the GFAP group remained 
blank. The results confirm the presence ofDRG neurones and astrocytes in this DRG cell 
preparation. 
5.4 Conclusions 
The above experiments have demonstrated that DRG cells can be prepared successfully 
in this laboratory, and that similar yields, viability and size distribution ofDRG cell types 
can be achieved compared with other laboratories that perform this procedure. However, 
the DRG cell preparation is not purely neuronal and contains up to 60% non-neuronal 
cells. Immunocytochemical staining identified the presence of astrocytes whilst some 
Schwann cells were identified morphologically. Although astrocytes have never been 
shown to possess IP-receptor mRNA (Kitanaka et al., 1996) or respond to iloprost (Ito et 
al” 1992)，and no IP-receptors have been identified in Schwann cells, it is still possible 
that the non-neuronal cells present in the DRG cell preparation may contribute to IP-
receptor mediated responses. The majority of other workers using adult DRG cells have 
not published the purity of their cell preparations (Lindsay et al, 1989; White, 1996; 
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Smith et al., 1998) and have only published selective pictures at lower cell densities 
which apparently do not possess many non-neuronal cells. This is also the case with our 
low cell density photographs (Fig. 5A), but it is clear that at the higher cell densities (Fig. 
5B) large quantities of non-neuronal cells are present. In an attempt to solve this problem 
. 
we have tried to identify the cells responsible for responding to agonists by measuring 
h 
j . 
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6.1 Dorsal root ganglion cell preparation 
The following method represents the finalised procedure based on results of preliminary 
experiments described in Chapter 5. 
Male Sprague Dawley rats (150 g - 200 g) were anaesthetised and their DRG 
removed as described in section 5.2.1. Once removed, the DRG were treated with 0.125% 
collagenase for 3 h (37°C, 5% CO2) followed by 0.25% trypsin for 30 min (37�C, 5% 
CO2). After rinsing in F14 complete medium the DRG were centrifuged (5 min, 43 x g, 
p 20�C) and the supernatant removed. The DRG were then resuspended in 2 ml of DNase 
(0.04%) and soybean trypsin inhibitor (0.05%) solution, and passed through a flame 
polished salinized Pasteur pipette in order to form a single-cell suspension. The 
dissociated cell suspension from each rat was divided into two and placed into 15 ml 
conical tissue culture tubes. To these tubes an equal volume ofBSA (15%, w/v) was 
added underneath the cell suspension. The tubes were then centrifuged (96 x g, 10 min, 
20�C), causing the neuronal cells to form a pellet and the myelin and cell debris to be 
trapped between the layers of BSA and medium. The pelleted cells were then removed 
using a salinized Pasteur pipette and washed in F14 complete media followed by 
: centrifugation (43 x g, 5 min, 20�C). The resulting supernatant was discarded and the 
s' 
pellet resuspended in 500 ^1 F14 complete medium and the cell yield counted. Neuronal 
cell yields were typically 120,000 - 180,000 cells/rat, whilst cell purity and viability were 
;j • 







The DRG cells were then plated (5 - 150 ^1) onto poly-DL-omithine/laminin-
coated wells at the cell density required for a particular experiment. After 1 h (37°C, 5% 
CO2) the cells were covered with 1 ml F14 complete medium, supplemented with NGF 
(50 ng/ml) and Ara C (10 ^iM). In experiments where cells were grown for more than 5 
days, the medium was changed every 3 - 4 days. 
6.1.1 Preparation of tissue culture plates and coverslips. 
Prior to use, tissue culture ware must be coated with poly-DL-omithine and Iaminin in 
order to support neuronal cell outgrowth. Poly-DL-omithine is coated to a final 
concentration of 500 ^g/ml, 18 h prior to the cell preparation. The following day any 
excess poly-DL-omithine is aspirated and the wells/coverslips rinsed 3 times with sterile 
錢 
PBSA immediately prior to addition of laminin. Laminin is added to each well/coverslip 
to a final concentration of 5 ^g/ml and left for at least 1 h. Immediately prior to plating 
the DRG cells, the excess laminin is removed and the wells/coverslips washed 3 times 
with sterile ultra-pure H2O. 
6.1.2 Preparation of Pasteur pipettes 
Prior to use, all glass Pasteur pipettes that will come into contact with the DRG cell 
preparation must first be salinized to prevent the cells from adhering to the glass. In order 
to achieve this, Pasteur pipettes are immersed in a 2% (v/v) solution of dimethyl dichloro 
silane in toluene for 30 min. This is followed by rinsing once with methanol and finally 
with ultra-pure H2O. Some ofthe Pasteur pipettes used need to be flame polished in order 
to create a fine tip on the pipette. This is achieved by passing a salinized pipette through 
the blue flame ofaBunsen burner. All pipettes are then autoclaved before use. 
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6.2 Measurement of adenylate cyclase activity 
6.2.1 Introduction 
The activity of adenylate cyclase, the enzyme that catalyses the formation of cyclic AMP 
from ATP, is usually measured in one of two ways: (a) using a commercially available 
cyclic AMP enzyme immunoassay (EIA) kit; or (b) by labelling cells with [^]-adenine 
and measuring the conversion of [^]-ATP to [^]-cyclic AMP. Whilst method (a) has 
the advantage of being able to quantitatively measure the amount of cyclic AMP 
produced, our attempts at using cyclic AMP EIA kits were highly ineffective. The 
slightest organic impurities and dilution of the samples caused erratic results. On the 
other hand, method (b), despite only being able to provide qualitative measurements of 
cyclic AMP production and also having additional safety complications due to the use of 
radioisotopes, did have the advantages of high sensitivity and reproducibility, as 
demonstrated previously by other work conducted in this laboratory (Wise & Jones, 
1994； Wise, 1996; Wise et al., 1998a). For these reasons method (b) was chosen, details 
ofwhich are described in sections 6.2.2 and 6.2.3. 
The phosphodiesterase inhibitor iso-butyl-methyl-xanthine (IBMX) was included 
in the assay buffer to prevent the breakdown of cyclic AMP, and the non-selective 
cyclooxygenase (COX) inhibitor, indomethacin, was added to prevent endogenous 
production of prostaglandins. 
6.2.2 Preparation of columns 
Dowex columns (AG 50W-X4) were prepared by mixing 50 g of dowex with 100 ml HC1 
(1 M) and placing evenly in 50 Bio-Rad chromatography columns. The columns were 
washed with 4 ml HC1 (1 M), followed by 10 ml ultra-pure H2O prior to the experiment. 
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Alumina columns were prepared by adding 0.6 g of neutral alumina to each of 50 
columns, followed by 8 ml imidazole buffer (0.1 M, pH 7.5). These columns are 
reusable; dowex columns were rinsed with 4 ml HC1 (1 M), followed by 10 ml ultra-pure 
1^0，and alumina columns were rinsed with 8 ml imidazole buffer (0.1 M, pH 7.5)，prior 
to use. 
6.2.3 Measurement of [^H]-cyclic AMP production 
Cyclic AMP production in adult rat DRG cells was determined by measuring the 
conversion of [^]-ATP to [^]-cyclic AMP according to (Barber et al, 1980). Eighteen 
hours prior to the assay, DRG cells (500 - 15,000 cells/well, 24-well plate) were 
incubated with 2 ^Ci/ml [^]-adenine (37�C, 5% CO2). On the day of the experiment the 
medium was carefully aspirated and the cells were washed twice with 1 ml modified 
HEPES buffer containing IBMX (1 mM) and indomethacin (3 i^M). The cells were then 
covered with 0.5 ml ofthe same buffer and incubated with the test compounds or vehicle 
for 30 min in a water bath at 37�C. The reaction was then stopped by the addition of 0.5 
ml ice-cold TCA and ATP solution to a final concentration of 5% and 1 mM, 
respectively. The samples were then kept at 4�C for at least 1 h before column separation. 
[^]-cyclic AMP was separated from total [^]-adenine nucleotides (AXP) by 
column chromatography using dowex and alumina in a method adapted from Salomon et 
al” (1974). The reaction samples were placed into dowex columns followed by 3 ml 
ultra-pure H2O. The eluant was collected into 20 ml scintillation vials and mixed with 10 
ml scintillant (Optiphase Hi-safe 3). These samples were then counted in a liquid 
— scintillation counter (Beckman LS6000) to determine the total [^]-AXP activity. The 
dowex columns were then placed over the alumina columns and rinsed with 10 ml ultra-
pure H2O. Once the water had completely passed through both sets of columns, the 
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alumina columns were placed above 20 ml scintillation vials and the [^H]-cyclic AMP 
eluted with 6 ml imidazole buffer (0.1 M). Again the eIuant was mixed with 10 ml 
scintillation fluid and counted in a liquid scintillation counter. Blank samples (i.e. no 
c^ls) were run through the columns in parallel to the test samples in order to determine 
the background count for the columns, and these values were then subtracted from all the 
test values. 
6.2.4 Data analysis 
Each experiment was performed in triplicate and cyclic AMP production is expressed as 
([3H]-cyclic AMP])/(total [^]-adenine nucleotides) x 1000. Agonist concentration-
response curves were fitted using GraphPad Prism (Ver.3) non-linear regression analysis, 
‘ with the minimum value for each curve being constrained to the mean basal value for 
each individual experiment. The pEC50 values (negative log of EC50 value) of these 
individual curves was calculated, and combined to give a mean 士 S.E.M. To account for 
the different levels of basal cyclic AMP production under different experimental 
conditions, the results were often expressed as fold basal cyclic AMP production, where 
fold basal is [stimulated cyclic AMP production] divided by [basal cyclic AMP 
production]. A fold basal value of unity therefore indicates a lack ofstimulation. 
Statistical levels of significance (p < 0.05) were calculated using one-factor 
analysis of variance. When levels of significance were detected a Newman-Keuls post-




6.3 Measurement of phospholipase C activity 
6.3.1 Introduction 
The activity of phospholipase C，the enzyme that results in formation of inositol 1，4，5-
triphosphate (Ins P3) and DAG was measured in DRG cells by determining the 
accumulation of [^]-inositol phosphates compared to total [^]-inositol phospholipids 
(Smith et al, 1998). This method was chosen as opposed to direct measurement ofIns P3 
by scintillation proximity assay due to previous success of this method by other workers 
(Smith et al, 1998), and also due to the success and reproducibility of the cyclic AMP 
assay when using column chromatography methodology. 
Prior to the last decade, this type of direct agonist-stimulated PLC activity 
^ measurement was not possible due to rapid breakdown of w>^o-inositol-l-phosphate 
(Brown et al, 1984). However in 1982, Berridge et al showed that inclusion ofLiCl 
prevented the breakdown of m>'o-inositol-1 -phosphate, therefore allowing direct 
measurement of PLC activity. Previous studies have shown that [^]-myo-2-inositol is 
poorly absorbed by DRG cells (Smith et al, 1998), therefore high concentrations of [ ^ ] -
wyo-2-inositol were used in an attempt to increase cellular uptake. 
6.3.2 Preparation of columns 
Chromatography columns were prepared by mixing dowex (AG l-X8) resin with an 
� equal volume of ultra-pure H2O and placing 2 ml of this solution into 50 Bio-Rad 
chromatography columns, leaving approximately 1 ml of resin once dry. The columns 
were re-usable and were washed with 5 ml 2 M ammonium formate/0.1 M formic acid 





6.3.3 Measurement of [^]-inositol phosphate production 
Inositol phosphate production in DRG cells was measured using an adaptation of the 
method described by Smith et al. (1998). Eighteen hours prior to the assay, cells (15,000 
cells/well, 24-well plate) were incubated with 50 p,Ci/ml [^]-/w>'o-inositol (37°C，5% 
CO2). On the day of the experiment the medium was carefully aspirated and the cells 
were washed twice with 1 ml modified HEPES buffer. The cells were then covered with 
0.5 ml ofthe same buffer containing LiCl (20 mM) and incubated for 10 min at 37°C in a 
water bath. The test compounds or vehicle were then added for a further 30 min. The 
plates were then placed on ice, the buffer was aspirated and 750 ^1 formic acid (20 mM) 
was added to each well. The samples were then kept at 4°C for at least 1 h before column 
separation. 
'' [^]-inositol phosphates were separated from the total [^]-inositol phospholipids 
by column separation in a method adapted from Brown et al. (1984). Immediately prior 
to the column separation, the dowex columns were washed with 5 ml of 2 M ammonium 
formate/0.1 M formic acid, followed by 2 ml ultra-pure H2O and 2 ml ammonia solution. 
The columns were then placed over 20 ml scintillation vials and the entire 750 i^l formic 
acid extract was loaded onto the columns, immediately followed by 3 ml ammonia 
solution. This is the total [^]-inositol phospholipid fraction to which 7.5 ml scintillant 
(Optiphase Hi-safe 3) was added and the contents mixed thoroughly and counted in a 
liquid scintillation counter. 
, The columns were then placed over a waste container and 4 ml 40 mM 
ammonium formate/0.1 M formic acid solution was added to each column. The columns 
were then placed over a new set of scintillation vials and 5 ml 2 M ammonium 
). 3 
formate/0.1 M formic acid solution was added to elute the [ H]-inositol phosphates, to 
I . 








scintillation counter. Blank samples (i.e. no cells) were run through the columns in 
parallel to the test samples in order to determine the background count for the columns, 
and these values were then subtracted from all the test values. 
•� 
6.3.4 Data analysis 
Each experiment was performed in triplicate and inositol phosphate production is 
expressed as % conversion, i.e. ([^]-inositol phosphates)/(total [^]-inositol 
phospholipids) x 100%. Agonist concentration-response curves were fitted using 
GraphPad Prism (Ver.3) nonlinear regression analysis, with the minimum value for each 
curve being constrained to the mean basal value for each individual experiment. To 
account for the different levels of basal inositol phosphate production under different 
“ experimental conditions, the results were often expressed as fold basal inositol phosphate 
production, where fold basal is (stimulated inositol phosphate production) divided by 
(basal inositol phosphate production). A fold basal value of unity therefore represents a 
lack of stimulation. 
Statistical levels of significance (p < 0.05) were calculated using one-factor 
analysis of variance. When levels of significance were detected a Newman-Keuls post-
hok test was applied. 
2+ 
6.4 Measurement of [Ca ]i 
【.、 
6.4.1 Introduction 
The concentration of intracellular calcium ([Ca^^]i) was measured using the MiraCal PRO 
？； 
； ratio imaging system which measures the fluorescence emitted from Fura-2 loaded cells. 










When the DRG cells are stimulated with a Ca^^-mobilising agonist, the changes in 
fluorescence allows the user to record changes in [Ca^^]i within the cell in real time. 
Since the intensity of the fluorescence is directly proportional to the [Ca^^]j, it is therefore 
2+ 
possible to assess the effect of a particular agonist on Ca release in an individual cell at 
a certain time. 
The [Ca2+]i was calculated automatically by the MiraCal PRO software using the 
equation described by Grynkiewicz et al. (1985): 
[Ca2+]i = Kd P (R-Rmin) / (Rmax-R) 
where Kd is the dissociation constant for the Fura-2 dye (224 nM at 37°C)，R is the ratio 
— of fluorescence (F340/F380)，Rmin and Rmax are the ratio of fluorescence when the dye is 
completely free of Ca]+ and saturated with Ca^^ respectively, and p is the ratio of 
saturated to free fluorescence at 380 nm. Calibration for determining the values of Rmin, 
Rmax and p was performed by using fura-2 free acid solutions. 
6.4.2 Preparation of cells 
DRG cells were plated onto poly-DL-omithine/laminin-coated glass coverslips (13 mm, 
2,000 cells/coverslip). The coverslips were then placed in wells (6-well plate) containing 
2 ml F14 complete medium, supplemented with NGF (50 ng/ml) and Ara C (10 i^M) and 
cultured at 37°C, 5% CO2. After 5 days in culture, the medium was aspirated from the 
r� 
wells and replaced with modified HEPES buffer containing Fura-2-AM (3 i^M) and BSA 
(1 rng/ml) fNadal et al., 1996). Following 30 min incubation at 37�C, the cells were 
washed and re-immersed in modified HEPES buffer containing indomethacin (3 i^M). 






6.4.3 Measurement of Fura-2 fluorescence 
Fura-2 fluorescence was measured using a MiraCal PRO ratio imaging fluorescence 
microscope and performed according to Gilabert & McNaughton (1997). The coverslips 
wkh the fura-2 loaded cells attached were placed in stainless steel coverslip holders that 
had been greased with high vacuum silicone grease to prevent leakage from the resulting 
chamber. The cells were then re-immersed in 500 ^1 of prewarmed modified HEPES 
buffer containing indomethacin (3 i^M), and then the entire chamber inserted into a 
temperature controlled chamber holder. The cells were allowed to settle for 2 min at a 
constant temperature of 37°C and bright field light was then used to focus the image. An 
aliquot (5 |il) ofKCl (50 mM final concentration) was then added to the chamber and the 
fluorescence was read at wavelengths of 340 and 380 nm every 0.8 sec for 5 min. This 
^ was followed by addition of 5 i^l capsaicin (100 [xM final concentration) for 5 min and 5 
p,l of selected agonist for a further 5 min. Background fluorescence at both wavelengths 
was measured and subtracted from all subsequent calculations. 
1 
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6.5 Measurement of neuropeptides 
6.5.1 Introduction 
Measurement of the neuropeptides CGRP and substance P were performed by adaptation 
of methods described by Hingtgen & Vasko (1994) and White (1996). The concentration 
丨 of neuropeptide released into the medium, and the total cell neuropeptide content was 
: measured in order to express the results in terms of fractional release. Enzyme-







immunoassays (RIA) since the sensitivity of these assays was comparable, therefore there 
was no apparent justification in using radioisotopes. Bacitracin was included in the assays 
to prevent the breakdown of the neuropeptides and indomethacin to prevent endogenous 
pFoduction of prostaglandins. 
6.5.2 Preparation of cells 
DRG cells were prepared as previously described in section 6.1 and plated onto poly-DL-
omithine/laminin-coated plates (24-well/plate) at a cell density of 150,000 cells/well. The 
cells were then incubated (37�C，5% CO2) for 14 days in F14 complete media in the 
presence of NGF (50 ng/ml) and Ara C (10 |iM), the media being changed every 3 - 4 
days. 
On the day of the assay, the medium was carefully aspirated and the cells washed 
twice with 1 ml modified HEPES buffer containing bacitracin (0.02 mM), indomethacin 
(3 ^iM) and BSA (0.1%, w/v). The cells were then covered with 0.5 ml of the same buffer 
and incubated for 10 min in a water bath at 37�C in order to determine the basal release of 
neuropeptide. The buffer was then collected on ice and fresh buffer added to the wells. 
The cells were then incubated for a further 10 min, but this time in the presence of test 
compounds or vehicle, in order to determine the stimulated neuropeptide release. These 
buffer samples were also collected and the remaining cellular fraction lysed with the 
addition of4% acetic acid. Neuropeptides in the cellular fraction were purified using Sep-
Pak cartridges (see section 6.5.5) and vacuum centrifuged to remove any remaining 
organic solvents. All samples were frozen and freeze-dried to await measurement. All 
experiments were performed in triplicate. 
Calcitonin gene-related peptide (CGRP) and substance P measurement was 
performed using EIA kits (Cayman). The basal, stimulated and cellular samples were 
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reconstituted in EIA buffer and divided into two, half for the CGRP assay and half for the 
substance P assay. Each sample was then assayed in duplicate at least at 2 different 
dilutions. A standard curve was constructed using standards supplied in the kit. 
� 
6.5.3 CGRP assay 
Both human and rat CGRP assays were used. Both are competitive EIA's based on the 
double-antibody sandwich technique, where the 96 well-microtiter plate supplied in the 
kit was precoated with a monoclonal antibody specific to CGRP. This antibody will bind 
to any CGRP introduced into the well be it sample or standard. When an 
acetylcholinesterase (AChE) antibody is added to the well, this forms a sandwich with the 
CGRP antibody by binding to different parts of the CGRP molecule. Upon addition of the 
^ Ellman's reagent, the sample will tum yellow with an intensity proportional to the 
amount of CGRP present in the well. 
6.5.4 Substance P assay 
The substance P assay used was a competitive EIA, which is based on the competition 
between free substance P and a substance P tracer (which is linked to a AChE molecule) 
for a limited number of substance P-specific rabbit antiserum binding sites. The 
concentration of the substance P tracer is held constant whilst the concentration offree 
substance P varies. Therefore，the amount of substance P tracer able to bind to the rabbit 
antiserum will be inversely proportional to the concentration of free substance P in the 
well. The substance P-rabbit antiserum complex is then able to attach to the mouse 
monoclonal antibody that has been precoated onto the well. When the Ellman's reagent is 
added to the well, a yellow colour develops with an intensity that is inversely 
proportional to the amount of free substance P in the well. 
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6.5.5 Purification of samples using Sep-Pak cartridges 
Cellular fraction samples were purified using reverse phase Sep-Pak cartridges. Passing 5 
ml HPLC grade methanol followed by 5 ml ultra pure water through the cartridge 
activated the cartridges. The sample was then passed slowly (about 2 ml/min) through the 
cartridge and then washed with 10 ml 4% acetic acid. Passing a solution of 90% ethanol, 
9.6% water and 0.4% acetic acid through the Sep-Pak cartridge then eluted the 
neuropeptides. Finally the sample was vacuum centrifuged to remove any organic 
solvents and frozen until assaying. Immediately prior to assaying the sample was 




Characterisation of prostacyclin receptors on adult rat dorsal 
rpot ganglion cells 
7.1 Stimulation of adenylate cyclase 
7.1.1 Introduction 
In recent years there has been increasing speculation on the role of prostanoid receptor-
mediated responses in relation to hyperalgesia. Currently at the forefront ofthis debate is 
whether EP2/4-receptors or IP-receptors are primarily responsible for these responses. In 
the absence of any selective EP2/4 or IP-receptor antagonists, characterisation of these 
responses has therefore relied on comparing the rank order of agonist potency. Since IP-
receptors and EP2/4-receptors positively couple to adenylate cyclase via Gs, it is therefore 
possible to directly measure the effect of prostanoids on these receptors in adult rat DRG 
cells by comparing cyclic AMP production. Indeed, recent studies by Smith et al. (1998) 
and Murata et al. (1997) have shown that the IP-receptor is probably the major prostanoid 
receptor involved in hyperalgesia. However, the majority of the work involving adenylate 
cyclase activity in the aforementioned study was carried out on F-11 cells in order to save 
on the time-consuming DRG cell preparation. The present study follows on from of the 
work carried out by Smith et al. (1998) but focuses primarily on the characterisation of 
the IP-receptor in adult rat DRG cells. However, since prostacyclin and PGE2 share many 
common properties with regard to nociception, we have often included PGE2 alongside 
IP-receptor agonists for comparison. Therefore we will also present experiments which 
attempt to determine the receptor targets for PGE2. Furthermore, we have also 
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investigated the G-protein coupling properties of the IP-receptor using cholera toxin and 
pertussis toxin. If IP-receptor-stimulated responses are mediated via coupling to Gs, then 
cholera toxin should prevent this interaction because cholera toxin causes uncoupling of 
Gs from the receptor, effectively switching Gs "permanently on." If any of the IP-
receptor-stimulated responses are mediated by Gj, then pertussis toxin, which inhibits Gi, 
will also inhibit IP-agonist signalling. Cyclic AMP production was measured as described 
in section 6.2. 
7.1.2 Agonist concentration-response curves 
The concentration-response relationship of cicaprost, iloprost, PGEi, PGE2, and BMY 
45778 to stimulate cyclic AMP production was investigated in DRG cells (15,000 
cells/well, 24-well plate). The effect of the direct adenylate cyclase activator forskolin 
(Laurenza et al, 1989) was also investigated. The cells were stimulated with various 
concentrations of agonist for 30 min in the presence of IBMX (1 mM) and indomethacin 
(3 _ . 
The concentration-response relationships of prostanoid mimetics on cyclic AMP 
production in adult rat DRG cells are shown in Figure 9，with indicators of potency and 
efficacy shown in Table 2. The specific IP-receptor agonists cicaprost and iloprost were 
equipotent with EC50 values of 22 and 28 nM, respectively, and had similar maximum 
responses of3.28 and 3.26 fold basal, respectively. The EP-receptor agonist PGE2 had a 
higher EC50 of 167 nM than the prostacyclin mimetics and a maximum response only 
70% that of cicaprost and iloprost. PGEi had a similar EC50 value (185 nM) as PGE2 but 
exhibited a higher maximal response than cicaprost and iloprost (118%), suggesting that 
PGEi is acting on both IP-receptors and EP2/4-receptors in DRG cells. The IP-receptor 
partial agonist BMY 45778 only produced a small increase in cyclic AMP production in 
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these cells. Stimulation of the cells with the direct adenylate cyclase activator forskolin 
also produced cyclic AMP in a concentration-dependent manner, with an EC50 value of 
2.89 ^M (Fig. 10). Forskolin at concentrations of 50 - 75 nM gave similar responses to 
the^  maximum response of iloprost, therefore these concentrations were used in 







Agonist pEC50 Maximum response n 
(cyclic AMP production) 
~~~Cicaprost 7.65±0.34 8.51 ±0.32 4~~~ 
Iloprost 7.55土0.22 8.90土0.91 4 
PGEi 6 . 7 3 ± 0 . 2 1 1 0 . 3 1 ± 1 . 6 3 5 
: i 
PGE2 6.78士0.29 6.09土0.92 4 
Table 2. Prostanoid-stimulated cyclic AMP production in adult rat DRG cells. Results 
represent mean 土 S.E.M. of experiments performed in triplicate. pEC50 is the negative log 
ofthe EC50 value, calculated as described in section 6.2.4. 
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Figure 9. Effect of IP and EP-receptor agonists on cyclic AMP production in adult rat 
DRG cells. Results represent mean 士 S.E.M. of 4 - 5 experiments (except for 
BMY45778, n = 1), each performed in triplicate. Basal cyclic AMP production measured 
in the presence of indomethacin (3 i^M) and IBMX (1 mM) was 2.57 土 0.12 (n = 6). 
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Figure 10. Effect of forskolin on cyclic AMP production in adult rat DRG cells. Results 
represent mean 士 S.E.M. of 4 - 6 experiments, each performed in triplicate. Basal cyclic 
AMP production measured in the presence of indomethacin (3 i^M) and IBMX (1 mM) 
was 2.57±0.12(n = 6). 
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7.1.3 Cross-desensitisation experiments 
In order to try to identify the site of action of PGE2, we looked for cross-desensitisation 
between PGE2 and iloprost. If PGE2 was stimulating adenylate cyclase in DRG cells via 
th^ IP-receptor, then pretreatment of DRG cells with iloprost should downregulate both 
the iloprost and PGE2-mediated signalling. Firstly, we needed to show that homologous 
desensitisation could be observed to IP-receptor and EP-receptor agonists in our DRG 
cell preparation. DRG cells were incubated with either iloprost (10 ^iM), PGEi (10 |iM), 
PGE2 (PGE2) or forskolin (75 nM) for 0 h，2 h or 18 h. Following incubation, the treated 
cells were washed twice and then stimulated with the same agonist at the same 
concentration (Fig. 11). Following the 2 h pretreatment, iloprost and PGEi caused a 
reduction in their own responses to 82% of the untreated response whilst PGE2 and 
forskolin failed to reduce their own responses. The control response after 2 h was also 
reduced to 72%. Treatment with iloprost, PGEi or PGE2 for 18 h all caused reduction in 
subsequent challenges from the same agonists of 54%, 49% and 77% of the untreated 
response respectively. Response to forskolin was not affected but basal levels of cyclic 
AMP were reduced to 90% of the untreated response. 
Since all receptor mediated responses were reduced after 18 h we therefore 
investigated the effect ofagonist pretreatment by adding iloprost (10 _，P G E i (10 _ 
or PGE2 (10 i^M) to the DRG cells for 18 h prior to washing and assaying as usual. A 
non-prostanoid Gs-coupled receptor agonist NECA (10 \iM) was also included to see if 
any observed desensitisation was homologous or heterologous in character. Forskolin (10 
pM) was also included to ensure that any downregulation of the response was receptor-
mediated and notjust the result of elevated cyclic AMP production. Responses following 
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agonist pretreatment are expressed as a percentage of the responses following control 
(buffer) pretreatment. 
The results from 2 experiments confirmed our expectations (Fig. 12). Iloprost 
pfetreatment downregulated responses to iloprost itself (65% control) and to PGEi (72% 
control), but not to PGE2 (100% control). Pretreatment with PGE2 downregulated 
subsequent responses to both PGE2 (55% control) and PGEi (89% control), but had no 
effect on the response to iloprost (118% control). And pretreatment with PGEi 
downregulated subsequent adenylate cyclase responses to PGEi (65% control), PGE2 
(73% control) and to iloprost (91% control). 
Stimulation by forskolin following all pretreatment conditions tended to produce 
an enhanced response. Since forskolin can act synergistically with Gs-coupled receptor 
agonists (Wise et al, 1998b), the experiment was repeated with an increased number of 
washes (from 2 to 4) in order to ensure that the end response was not due to the continued 
presence of the prostanoid receptor agonist (Fig. 13). Results from this modified 
experiment confirmed those obtained previously (Fig. 12), and show that the apparent 
increased response to forskolin following agonist pretreatment was indeed eliminated by 
increasing the number ofwashes. 
Under no circumstances was the response to NECA downregulated by prostanoid 
receptor agonist pretreatment ofDRG cells, suggesting that the downregulation described 
above is due to homologous rather than heterologous desensitisation. It is presently 
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Figure 11. Time course of homologous desensitisation of responses in adult rat DRG 
cells. Results represent mean 土 S.E.M. of 2 experiments, each performed in triplicate. 
Basal cyclic AMP production measured in the presence of indomethacin (3 ^M) and 
IBMX (1 mM) was 3.62 土 0.62 (n = 2). 
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Figure 12. Cross-desensitisation experiment. Adult rat DRG cells were preincubated for 
18 h with prostanoid receptor agonists or forskolin. Adenylate cyclase responses to 
iloprost (I, 10 |iM), PGEi (Ei, 10 i^M), PGE2 OE2, 10 i^M), forskolin (F, 75 nM) and 
NECA fN，10 i^M) were assayed following 2 washes. Data is taken from one of two 
experiments, performed in triplicate, vertical lines represent S.E.M. 
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Figure 13. Cross-desensitisation experiment. Adult rat DRG cells were preincubated for 
18 h with prostanoid receptor agonists or forskolin. Adenylate cyclase responses to 
iloprost (I, 10 M-M), PGEi (Ei, 10 i^M), PGE2 (E2, 10 pM), forskolin (F, 75 nM) and 
cicaprost (C, 1 i^M) were assayed following 4 washes. Data is taken from one 





7.1.4 Evidence for EP3-recept0rs 
.1: 
In order to assess the contribution of EP3-recept0rs to the adenylate cyclase response of 
PGE2, the DRG cells were incubated for 15 min with the EP3-recept0r agonist, 
stilprostone (1 p,M) (Fig. 14). EP3-recept0rs are coupled negatively to adenylate cyclase, 
and their presence would be expected to inhibit the overall response to PGE2. However, 
sulprostone failed to significantly inhibit the responses to PGE2 (10 ^M), cicaprost (100 
nM), and to forskolin (75 nM), suggesting an absence of EP3-recept0rs in adult rat DRG 
cells. 
7.1.5 G-protein coupling of the IP-receptor 
In order to confirm the G-protein coupling properties of the IP-receptor, DRG cells were 
treated with cholera toxin (150 ng/ml) or pertussis toxin (200 ng/ml) for 18 h and their 
effect on subsequent stimulation by cicaprost (100 nM) and forskolin (50 nM) was 
measured (Fig. 15). The concentration of forskolin (50 nM) was chosen because it caused 
a similar increase in cyclic AMP production to the EC50 concentration of cicaprost. As 
expected, following cholera toxin treatment there was an increase in basal level of cyclic 
: AMP production from 2.2 土 0.3 in the control cells to 95.8 土 6.2 in the cholera toxin-
treated cells. When expressed as fold basal cyclic AMP, the cicaprost response in the 
presence of cholera toxin was significantly lower than control (p < 0.001) and in fact 
failed to increase cyclic AMP production above basal, as was the response to forskolin (p 
: < 0.001) in the presence of cholera toxin when compared to control. Pretreatment 
overnight with pertussis toxin significantly (p < 0.001) increased both cicaprost (4.23 土 
0.13 fold basal) and forskolin (6.40 土 0.23 fold basal)-stimulated cyclic AMP production. 
However, the pertussis toxin pretreatment also significantly (p < 0.001) reduced basal 




i '' p 
l I 




toxin-treated cells, possibly accounting for the apparent increase in response to cicaprost 
and forskolin. 
7rl.6 Discussion 
The above results demonstrate that a number of prostanoid receptors are expressed in 
adult rat DRG cells. The high potency of prostacyclin mimetics, cicaprost and iloprost, in 
causing an increase in [^]-cyclic AMP production shows that the IP-receptor is more 
strongly coupled to adenylate cyclase activity than are EP2/4-receptors in adult rat DRG 
cells. The low maximum 0fPGE2 could be explained in a number of ways: (a) that PGE2 
is acting on the IP-receptor with low affinity, (b) that there is simultaneous activation of 
inhibitory Gi-coupled EP3-recept0rs, (c) that few EP2/4-receptors are present in this DRG 
cell population and (d) that the EP-receptor is not as efficient in coupling to activation of 
adenylate cyclase as the IP-receptor. Our desensitisation experiments demonstrate that 
the first explanation (a) is unlikely, since no cross-desensitisation was observed between 
iloprost and PGE2, thus confirming that PGE2 is unable to stimulate IP-receptors at these 
concentrations in these cells. Explanation (b) of simultaneous activation of both EP2/4-
receptors and EP3-recept0rs is also unlikely since the EP3-recept0r agonist sulprostone 
did not inhibit responses to cicaprost, PGE2 or forskolin. Previous studies have also 
demonstrated that EP3 agonists such as sulprostone do not effect cicaprost or forskolin-
stimulated cyclic AMP production in DRG cells (Smith et al., 1998). These results are 
perhaps surprising since high levels of mRNA for EP3-recept0rs have been identified in 
mouse and rat dorsal root ganglia (Oida et al., 1995; Nantel et aL, personal 
communication). A relatively low number of EP2/4-receptors could conceivably cause the 
lower maximum response of PGE2. Again, mRNA for EP4-recept0rs has been 
demonstrated in mouse (Oida et al, 1995) and rat DRG O^antel et aL, personal 
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communication). It therefore remains to be seen just how close the relationship is 
between receptor expression in terms of mRNA hybridisation studies and functional 
studies. 
� The high maximum response ofPGEi suggests that this agonist may be acting via 
both IP-receptors and EP2/4-receptors as expected since PGEi is a known agonist of both 
IP- and EP2/4-receptors in other cell types (Katsuyama et al., 1994). This theory is 
supported by the desensitisation experiments, since cross-desensitisation was observed 
between PGEi and iloprost, and between PGEi and PGE2. 
G-protein coupling properties of the IP-receptor were investigated. After 
pretreatment of DRG cells with cholera toxin, cicaprost failed to increase cyclic AMP 
levels above basal levels, thus confirming Namba et al. (1994) who showed that the 
cloned IP-receptor couples positively to adenylate cyclase via Gs. 
Pretreatment ovemight with pertussis toxin increased both cicaprost and 
forskolin-stimulated cyclic AMP production, but failed to increase basal adenylate 
cyclase activity. In fact, pertussis toxin pretreatment reduced basal cyclic AMP 
production, possibly accounting for the apparent increase in response to cicaprost and 
forskolin. Since there was no increase in basal adenylate cyclase activity in the presence 
._‘、 
of pertussis toxin it is unlikely that an endogenous factor is released in our cell 
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Figure 14. Effect of sulprostone (1 i^M) on cyclic AMP production by cicaprost (100 
nM), PGE2 (10 |iM) and forskolin (75 nM). Basal cyclic AMP production was: control = 
3.62 土 0.77; sulprostone = 3.16 土 0.16. Data represents mean 士 S.E.M. of3 experiments, 
each experiment performed in triplicate. Sulprostone had no effect on basal or stimulated 
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Figure 15. Effect of cholera toxin and pertussis toxin on cyclic AMP production by 
cicaprost (100 nM) and forskolin (50 nM) in adult rat DRG cells expressed as cyclic 
AMP production (A) and fold basal (B). Basal cyclic AMP production: control = 2.2 土 
0.3; cholera toxin (CTx) = 95.8 土 6.2; pertussis toxin (PTx) = 1.3 土 0.2. (+ indicates 
significant difference (p < 0.05) from control basal). Data represent mean of 2 
experiments, each performed in triplicate, bars indicate S.E.M. Levels of significance 
calculated using one way analysis ofvariance. 
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7.1.7 Conclusions 
According to Smith et aL (1998)，rat DRG cells in vitro show little response to PGD2. 
Therefore, we might conclude that the IP-receptor is the predominant prostanoid receptor 
studied that couples to adenylate cyclase in adult rat DRG cells. The low maximum 
response and potency of PGE2 is unlikely to be due to stimulation of IP-receptors, or co-
stimulation ofEP2/4-receptors and EP3-recept0rs. It is therefore probably due to the EP2/4-
receptor either having low efficiency in coupling to adenylate cyclase or low receptor 
numbers. The high maximum response to PGEi in these cells is due to stimulation ofboth 
IP and EP2/EP4-receptors. And finally that the IP-receptor is positively coupled to 
adenylate cyclase via Gs but is unlikely to couple to Gj in adult rat DRG cells. 
7.2 Stimulation of phospholipase C 
7.2.1 Introduction 
In order to further characterise the role of prostacyclin in pain modulation, the effect of 
prostacyclin mimetics on inositol phosphate production was also investigated. The IP-
receptor is known to couple to Gq as well as Gs in rat DRG cells (Smith et al., 1998). It is 
therefore possible that the IP-receptor can directly cause an increase in inositol 
phosphates which could lead to release of Ca�+ and neuropeptides and thus be directly 
involved in signalling a pain response. This possibility is investigated below together 
with pretreatment of the DRG cells with pertussis toxin and cholera toxin to confirm the 
G-protein coupling of the IP-receptor during inositol phosphate production. Measurement 
of inositol phosphates was performed as described in section 6.3 unless otherwise stated. 
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7.2.2 Agonist concentration-response curves 
The ability of the prostacyclin mimetic cicaprost to stimulate PLC activity in adult rat 
DRG cells was investigated. It has been previously reported that cicaprost (100 nM) can 
evoke an increase in inositol phosphate production (Smith et al., 1998). Cicaprost (1 i^M) 
produced a small, but consistent increase in PLC activity (Fig. 16)，of 1.50 土 0.21 fold 
basal. Bradykinin at the same concentration produced an increase of 1.99 土 0.55 fold 
basal. However these responses are not significantly different from controls, and each 
response was much lower than produced by bradykinin (10 nM) and cicaprost (100 nM) 
in the only other comparable study (Smith et al, 1998). Forskolin (50 nM) produced a 
similar response to cicaprost, whereas a relatively high concentration of iloprost (10 ^M) 
produced no stimulation ofPLC activity. 
7.2.3 G-protein coupling 
Pretreatment of the DRG cells for 18 h with cholera toxin (150 ng/ml) caused a 
significantly decreased PLC response to cicaprost (control = 1.42 土 0.13，cholera toxin = 
0.97 士 0.12 fold basal (p < 0.05)) whilst cholera toxin pretreatment had no significant 
effect on the bradykinin response (Fig. 17). Pertussis toxin (200 ng/ml) had no significant 
effect on the response to cicaprost but caused a significant increase in the response to 
bradykinin (control 二 1.41 土 0.23，bradykinin = 2.01 土 0.15 fold basal (p < 0.05)). 
In an attempt to improve the sensitivity of this assay a number of measures were 
attempted. These included varying the concentration of ammonium formate so as to try 
and elute more of the bound [^]-inositol phosphates from the columns, and also 
measuring the [^]-inositol phosphates present in the reaction buffer as well as cellular 
content of [^]-inositol phosphates. Levels of [^]-inositol phosphates were measured at 
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each stage of the assay in order to ensure that no bound [^]-inositol phosphates were 
discarded accidentally during the washing stages. Unfortunately, all of these measures 
failed to detect large levels of bound [^]-inositol phosphates or improve the assay 
sensitivity. 
7.2.4 Discussion and Conclusions 
Cicaprost and bradykinin caused no significant increases in inositol-phosphate production 
above basal, this is perhaps surprising since other studies have had significant responses 
with lower concentrations of the same drugs (Smith et al, 1998). It appears that the cells 
have trouble in taking up the [^]-m;;o-inositol, which is not unexpected since previous 
workers have had difficulties with [^]-wyo-inositol uptake into DRG cells (Smith, 
‘ personal communication) but have overcome the problem by using relatively high 
concentrations of [^]-w>^o-inositol (50 ^iCi). We also used this high concentration of 
[^]-w>^o-inositol but apparently to no avail. However, subsequent work in this 
laboratory has found that incubating CHO cells with [^]-wyo-inositol for 2 days instead 
of ovemight, considerably improves sensitivity of the assay and may well be worth trying 
with DRG cells in the future. The reasons for cholera toxin causing a decrease in the 
cicaprost response, and pertussis toxin causing an increase to the bradykinin response is 
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Figure 16. Stimulation of inositol phosphate production in adult rat DRG cells. Cells 
were incubated with agonists for 30 min in the presence of indomethacin (3 i^M) and 
LiCl (10 mM). C 二 cicaprost, B 二 bradykinin, I = iloprost, and F = forskolin. Basal 
inositol phosphate production = 13.35 士 5.45% conversion. Data represents mean of 3 
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cicaprost (100 nM) and bradykinin (1 ^iM). Basal inositol phosphate production is: 
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way analysis of variance. 
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7.3 Stimulation of changes in [Ca^ ]^i 
7.3.1 Introduction 
Smce stimulation of Gq by the IP-receptor has been previously shown to cause an 
increase in inositol phosphate production (Smith et al, 1998)，it is of interest to see if 
stimulation ofthe DRG cells does indeed cause a release of Ca�+ from internal stores. By 
using the MiraCal PRO fluorescent imaging system it is possible to identify individual 
DRG cells and measure changes in [Ca^ ]^i in each cell. If the cell responds to KC1 it 
would confirm that the cell is indeed neuronal, since a contaminating non-neuronal cell 
should not respond to high K+ (Gilabert & McNaughton, 1997). Subsequent stimulation 
by capsaicin would confirm nociceptive capability of the particular DRG cell if an 
increase in [Ca^ ]^i was observed. And finally, if addition of iloprost caused an increase in 
[Ca2+]i it would suggest that prostacyclin does indeed have a direct nociceptive action. 
7.3.2 Preliminary results 
Measurement of changes in [Ca^ ]^i was performed on 12 DRG cells seen in one field of 
view on the fluorescent microscope as described in section 6.4. Stimulation ofthe DRG 
cells with 50 mM KC1 caused an increase in [Ca^ ]^i in all cells identified morphologically 
as DRG cells, thus confirming that these cells were indeed neuronal. Subsequent 
stimulation with capsaicin (1 p,M) also caused an increase in [Ca^ ]^j in 33% of the cells 
identified as neuronal by the KC1 challenge. Finally addition of 10 i^M iloprost showed a 
small increase in [Ca^ ]^i in 75% of the cells that responded to both KC1 and capsaicin 
challenge (Fig. 18). 
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Figure 18. Mean of total cellular responses to KC1 (50 mM), capsaisin (l ^M) and 
iloprost (10 i^M) on [Ca^^i in adult rat DRG cells. Results are from one experiment 
observing 12 DRG cells. 
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7.3.3 Discussion and Conclusions 
Previous studies have demonstrated that approximately 50% of the total neuronal 
population are capsaicin-sensitive and approximately 21% of all the neurones in DRG 
have the ability to produce substance P and respond to prostacyclin (Winter, 1987; Oida 
et al., 1995). Our result indicate that 33% of the cells present are capsaicin-sensitive, 75% 
of which can also respond to iloprost which equates to approximately 25% of the total 
neuronal population. The similarities of these results are remarkable since the response to 
KC1 was so great that it was difficult to see the subsequent responses to capsaicin or 
iloprost. 
In order to improve the visibility of the iloprost and capsaicin responses it was 
decided to alter the order of addition of agonists. Because capsaicin is expected to have a 
longer time-course response compared to KC1 and iloprost, we planned to add capsaicin 
last. However, at this point the fluorescent microscope ceased to work and subsequent 
experiments have not yet been possible. Furthermore, the use of a constantly perfused 
cell system may also improve the sensitivity of this type of assay. Of course the clear 
advantage of this assay is the ability to identify the types of cells responding to IP-
receptor agonists, a factor missing from our adenylate cyclase and PLC assays. 
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CHAPTER 8 
Neuropeptide release by adult rat dorsal root ganglion cells 
� 
8.1 Introduction 
As mentioned in chapter 2, the release of neuropeptides such as substance P and CGRP, 
is one of the underlying mechanisms in transmitting nociceptive and hyperalgesic signals. 
The effect of prostaglandins on neuropeptide release in neonatal and adult rat DRG cells 
is well documented and has shown that both PGE2 and PGI2 enhance subsequent 
responses to bradykinin and thus cause enhanced neuropeptide release (Hingtgen & 
Vasko, 1994; Vasko et al., 1994; Stucky et al, 1996; White, 1996). This mechanism of 
sensitisation that causes hyperalgesia is believed to be dependent on cyclic AMP, since 
the direct activator of adenylate cyclase forskolin, produces similar sensitising effects 
(Hingtgen et al, 1995). 
In addition to the hyperalgesic effect of PGI2, studies have also demonstrated that 
PGI2 and carbacyclin can cause increases in substance P and CGRP release above basal 
in embryonic rat DRG sensory neurones (Hingtgen & Vasko, 1994). The cyclic AMP 
mimetics forskolin and cholera toxin failed to cause neuropeptide release, despite being 
able to cause enhancement of bradykinin and capsaicin-mediated responses. Since the IP-
receptor is able to couple to both adenylate cyclase via Gs and to PLC via Gq, it is 
therefore possible that the sensitising effects of prostacyclin is mediated via cyclic AMP, 
whereas direct release of neuropeptides by prostacyclin mimetics could be via PLC and 
subsequent stimulation ofPKC and Ca^ +. 
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The following experiments therefore aim to determine whether PGI2 can cause 
direct release of neuropeptides, and/or can potentiate stimulated neuropeptide release 
from adult rat DRG cells. 
� 
8.2 Methods and Results 
Measurement of cellular neuropeptide content and neuropeptide release were performed 
as described in section 6.5 unless otherwise stated. Stimulation of adult rat DRG cells 
(150,000 cells/well, 24-well plate) with bradykinin (100 nM - 10 i^M), KC1 (40 mM) or 
capsaicin (100 nM) for 20 min, all failed to cause detectable substance P or CGRP release 
above basal. Co-stimulation of the cells with bradykinin (10 ^M) or capsaicin (100 nM) 
with iloprost (1 \xM) also failed to elevate basal neuropeptide release. 
t' 
Measurement of total cellular neuropeptide content in two separate experiments, 
each performed in triplicate, demonstrated the presence of CGRP (437 士 149 pg/ml) in 
our cells. Unfortunately the substance P assays either failed to give reliable standard 
curves or gave erratic results when the samples were diluted in order to fit the standard 
curve. Known amounts of Substance P were therefore included in some ofthe samples in 
order to determine if the level of substance P was being effected during the purification 
step or during dilution of the samples. However, subsequent measurement of these 
substance P spiked samples also gave nonsensical results. 
8.3 Discussion 
Unfortunately no detectable levels of neuropeptides were released from our DRG cells. 
The expected levels of neuropeptide described in previous studies were within the limits 
of the ELA used, although previous studies had all used radioimmuno assays (RIAs). 
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EIAs were chosen since they reportedly had similar sensitivity as RIAs, without the risk 
of using radioisotopes. 
There are a number of possibilities why the release studies did not work, the most 
likely being that the EIAs used were not sensitive enough or that the peptides had 
degraded before being assayed. Every precaution had been taken to ensure that the 
neuropeptides did not degrade, including assaying in the presence of bacitracin and 
keeping the samples on ice wherever possible. Another possibility is that the cells in our 
preparation are all large diameter non-neuropeptide containing neurones. This 
explanation is however unlikely since our size distribution studies have shown similar 
size distribution of cells as other workers. We also have evidence of nociceptive neurones 
in our [Ca^^]j studies that showed that 33% of the neurones responded to capsaicin, and 
also large amounts of CGRP was found in the total cell content fraction suggesting 
nociceptive capability. 
8.4 Conclusions 
In conclusion, we have demonstrated that DRG cells prepared in this laboratory 
do contain CGRP and therefore have nociceptive capabilities. Due to difficulties with the 
substance P EIA, it is not possible to determine if substance P is present in our DRG cells 
at this time. Poor assay sensitivity could also account for the lack of detectable 
neuropeptide release by KC1, bradykinin and capsaicin. 
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CHAPTER 9 
Regulation of prostacyclin receptors on adult rat DRG cells 
� 
9.1 Introduction 
In view of the high number of non-neuronal cells in our DRG cell preparation 
(approximately 60%), it was important to clarify the role of these non-neuronal cells in 
the cyclic AMP response to IP-receptor agonists. In order to achieve this, an attempt was 
made to remove the DRG cells from the preparation and thus only have non-neuronal 
cells present. To our surprise, the non-neuronal cell preparation gave a much higher 
cyclic AMP response than the original DRG cell preparation. Further investigation 
however revealed that the non-neuronal cell preparation was contaminated with a small 
number ofDRG cells, which prompted us to look at DRG cells at different cell densities. 
The results of those findings are described below. DRG cells were prepared as described 
in section 6.1 and cyclic AMP production was measured as described in section 6.2. 
9.2 Contribution of non-neuronal cells 
Non-neuronal cells were prepared in an adaptation of the differential adhesion method 
(section 5.2.3.1). Briefly, the dissociated DRG cells (15,000 cells/well) were plated onto 
poly-DL-omithine/laminin-coated 24-well plates. After 1 h, fresh F14 complete medium 
was added and the neurones were removed by gently dislodging from the wells using a 
'. 
stream of medium from a Pasteur pipette. This process was repeated to ensure little or no 
neuronal cells remained, thus leaving a well with a representative amount of non-
neuronal cells. The cells were then covered with 1 ml F14 complete medium containing 
NGF (50 ng/ml) and Ara C (10 i^M) and cultured for 5 days (37�C, 5% CO2). 
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These non-neuronal cell preparations were then assayed for cyclic AMP 
production. Stimulation of the non-neuronal cells by 10 i^M iloprost produced a response 
of 38.17 士 11.06 fold basal in cyclic AMP production, whereas the corresponding 
naironal cell preparation (15,000 cells/well, 24-well plate) produced a 4.10 土 0.51 fold 
basal response of cyclic AMP (n = 2). 
9.3 Effect of DRG cell density 
During the development stage of the current study, we carried out experiments to 
determine which cell concentration would produce the best cyclic AMP response. We 
noticed that 30,000 cells/well produced less cyclic AMP than 15,000 cells/well (2.26 土 
0.47 and 3.10 士 0.42 fold basal respectively, n = 1). It was therefore conceivable that 
f' 
increased cyclic AMP production in the non-neuronal cell preparation was caused by a 
small number of contaminating DRG cells rather than the non-neuronal cells. DRG cells 
were therefore plated at different cell densities (500 - 15,000 cells/well, 24-well plate). 
Stimulation of the DRG cells with iloprost (10 i^M), PGEi (10 i^M) and PGE2 (10 |iM) 
all caused significant increases in cyclic AMP production with decreasing cell density 
when comparing 15,000 and 500 cells/well (p < 0.05), whereas stimulation with forskolin 
(50 nM) remained unchanged at all cell densities (Fig. 19). Cyclic AMP responses to a 
high concentration of forskolin (10 ^iM) was also unchanged at different cell densities 
( 1 5 , 0 0 0 cells/well 二 4 7 . 6 6 土 11.94, 10,000 cells/well 二 5 8 . 2 7 土 4 . 0 9， 5 , 0 0 0 cells/well = 
50.04 土 0.57 and 500 cells/well 二 57.36 土 23.29 fold basal). 
In order to ensure that the prostanoid mediated increases in cyclic AMP levels at 
low cell densities were not due to an artefact created from our manipulation ofthe data, 
the raw data for basal, iloprost (10 i^M) and forskolin (50 nM) stimulated cyclic AMP 
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levels were expressed as DPM (disintegrations per minute) per 1000 cells (Fig. 20). 
Figure 20 demonstrates that although basal and forskolin DPM levels increase slightly 
with decreased cell density, the response is far greater at lower cell densities due to 
ileprost. 
To determine if the increase responsiveness of DRG cells at low cell number 
represented a change in receptor affinity or efficacy, a concentration-response curve for 
iloprost was obtained using DRG cells at 500 cell/well (Fig. 21). The pEC50 values for 
iloprost were 7.55 土 0.22 and 7.07 土 0.03 at 15,000 and 500 cells/well, respectively. 
Efficacy values for iloprost, calculated as fold basal values, were significantly different Q) 
< 0.001) at 3.36 土 0.14 and 6.03 士 0.38 for 15,000 and 500 cells/well, respectively. 
t ‘ 
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Figure 19. Effect of DRG cell density on adenylate cyclase activity. Basal cyclic AMP 
production: 15,000 cells/well = 3.20 土 0.27; 10,000 cells/well = 3.51 士 0.30; 5,000 
cells/well = 3.70 士 0.30 and 500 cells/well = 2.91 士 0.19o/o conversion. Data represent 
mean of 2 - 5 experiments (15,000 and 500 n > 3, 10,000 and 5000 n > 2), each 
performed in triplicate, bars indicate S.E.M. Statistical levels of difference from 
responses in 15,000 cell/well were determined using one-factor analysis of variance 
followed by Newman-Keuls test (* 二 p < 0.05，*** p < 0.001). 
96 
'V 
E 4000"! • Basal 
%]^ • lloprost(10 i^M) 
^ 3000- T o Forskolin (50 nM) 
| o K 
o o 2000- \ 
, : l ^ 
(~ 1~~"— 1 1 
100 1000 10000 100000 
Cell density (DRG cells/well) 
Figure 20. Effect of DRG cell density on adenylate cyclase activity expressed as [ ^ ] -
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Figure 21. Effect of iloprost on DRG cell responses at different cell densities. Basal 
cyclic AMP production: 15,000 cells/well = 2.45 土 0.16; 500 cells/well = 2.16 土 0.28. 
Data represent mean of 6 experiments (15,000 cells/well) and 3 experiments (500 
cells/well), each performed in triplicate, bars indicate S.E.M. 
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9.4 Effect of indomethacin 
We have previously observed that DRG cells preincubated with high concentrations of 
IP-receptor agonists undergo homologous desensitisation (section 7.1.3). The most likely 
cause of this apparent downregulation of the IP-receptor mediated responses seen in 
Figure 19 is that more endogenously produced prostacyclin is generated by higher cell 
densities. Therefore, DRG cells were incubated with indomethacin (3 i^M) or vehicle for 
5 days in culture in order to inhibit any ongoing prostacyclin production. Since our 
previous work using spectrophotometric analysis had shown that the indomethacin was 
metabolised after 3 days in culture (data not shown), the F14 complete media containing 
NGF (50 ng/ml) and Ara C (10 i^M) and indomethacin or vehicle was replaced midway 
through the culture period. 
h� 
Results indicated that pretreatment of the DRG cells (15,000 cells/well, 24-well 
I 
I plate) with indomethacin (3 i^M) for 5 days, failed to significantly elevate the adenylate 
I 
i • 
I cyclase response to 10 i^M iloprost (fold basal response was 4.37 土 0.18，and 4.07 士 0.13 
I 
for control and indomethacin-treated groups, respectively, n 二 3). With this apparent lack 
of effect of indomethacin, it was necessary to demonstrate that indomethacin, at 3 p,M, 
j 
was indeed capable of inhibiting endogenous prostacyclin production. Therefore, since 
I j 
prostacyclin is too unstable to measure in biological samples, we measured its metabolite 
6-keto-PGFia in DRG cells following 5 days treatment with indomethacin (3 M-M) or 
vehicle control. Levels of 6-keto-PGFia were measured in either the media or the cell 
sample using a 6-keto-PGFia EIA kit. Preliminary results indicate that indomethacin does 
reduce endogenous 6-keto-PGFia from 501 土 103 pg/ml in the control group to 359 ± 39 
- -
pg/nil in the indomethacin group in the media samples, whilst no detectable levels of 6-
keto-PGFia were found in the cell sample (results are from one experiment performed in 
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triplicate and assayed in duplicate ). This assay was attempted a number of times but as 
with other EIA performed in this laboratory the success rate of obtaining a good standard 
curve and detectable levels of 6-keto-PGFia was low. 
� 
9.5 Contribution of endogenously-produced non-prostanoid ligands 
Another possible cause of the downregulation would be the presence ofan endogenously 
produced agonist for a Gj-coupled receptor. Indeed, pretreatment of the DRG cells 
ovemight with pertussis toxin did increase both cicaprost (100 nM) and forskolin (50 
nM)-stimulated adenylate cyclase activity (section 7.1.5), suggesting that pertussis toxin 
was able to remove some endogenous inhibitory tone. However, the pertussis toxin 
pretreatment did not elevate basal adenylate cyclase activity in these experiments. 
To further clarify matters, antagonists to adenosine Ai receptors (DPCPX) and 
opiate receptors (naltrexone) were used. These drugs were chosen because adenosine and 
opiates are likely to be produced in neuronal cell populations and are therefore good 
candidates for being responsible for the apparent inhibition of the IP-receptor mediated 
response at high cell concentrations. However, as seen in Figure 22, neither DPCPX (100 
nM) nor naltrexone (1 i^M) caused increases in basal adenylate cyclase activity or 
increases in iloprost-stimulated adenylate cyclase activity. The response of forskolin in 
the presence of either antagonist was also unaffected. 
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Figure 22. Effect of adenosine Ai-receptor antagonist (DPCPX) and opioid receptor 
antagonist (naltrexone) on adenylate cyclase activity in adult rat DRG cells. Antagonists 
were added for 15 min prior to control buffer or iloprost. Basal cyclic AMP production 
was: control = 2.67 土 0.95; DPCPX (100 nM) = 2.19 土 0.23; naltrexone (1 i^M) 二 2.36 土 
0.46. Results are mean 土 S.E.M. of 3 experiments, performed in triplicate. DPCPX and 
naltrexone had no effect on basal or stimulated cyclic AMP production ( p > 0.05, one 
way analysis of varience). 
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9.6 Effect of PKC activation 
Activation of PKC with phorbol-esters increases subsequent cyclic AMP responses by 
cicaprost and forskolin in DRG cells, UMR-106 osteoblast cells and mast cells, but cause 
a�reduction in cyclic AMP production with PGE2 in UMR-106 osteoblast cell lines and 
cultured mast cells (Khanin et al, 1999; Smith et al, 1998). These observations suggest 
that cyclic AMP production via EP2/4-receptors may have different regulatory pathways 
involving PKC to those ofIP-receptors. 
In order to determine whether or not activation of protein kinase C (PKC) could 
influence cyclic AMP production in DRG cells, the PKC-activating agent PMA (phorbol-
12-myristate-13-acetate) was used. Preincubation of the cells for 15 min with PMA (1 
p,M) caused no significant increase in basal cyclic AMP production (control 二 3.62 土 
5 ' 
0.77, PMA = 5.31 土 0.33 (p > 0.05)). Stimulation of the PMA-treated cells with forskolin 
(75 nM) significantly increased the cyclic AMP response (p < 0.05), however responses 
to cicaprost (100 nM) or PGE2 (10 i^M) in the presence of PMA were not significantly 
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Figure 23. Effect of PMA on adenylate cyclase activity in adult rat DRG cells. PMA (1 
i^M) was added for 15 min prior to test compounds. Basal cyclic AMP production was: 
control = 3.62 土 0.77; PMA = 5.31 士 0.33. Results are mean 土 S.E.M. o f3 experiments, 
performed in triplicate. Levels of significance (p < 0.05) calculated using one way 
analysis of variance, 
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9.7 Discussion 
The non-neuronal cell preparation suggested that the non-neuronal cells present in our 
DRG cell preparation could contribute to the cyclic AMP response. Although previous � 
studies have shown that astrocytes do increase cyclic AMP production in response to 
PGE2, iloprost was shown to have no effect (Ito et al, 1992). To date EP3, FP and TP-
receptor mRNA have been found but no evidence of IP-receptors has been found in 
astrocytes (Kitanaka et al, 1996). This lead us to investigate whether or not the high 
response in the non-neuronal cell preparation was in fact due to low numbers of 
contaminating DRG cells. Indeed, DRG cells plated at lower concentrations (500 
cells/well) produced significantly higher cyclic AMP responses than cells plated at higher 
cell densities (15,000 cells/well) to all three prostanoid mimetics iloprost, PGEi and 
PGE2. However, responses to forskolin (50 nM and 10 \xM) remained unchanged despite 
a decrease in cell number (Fig. 19). The cyclic AMP response to 50 nM forskolin was in 
the same range as the prostanoid agonist responses, demonstrating that the cell density-
dependent response was not an artefact of assay sensitivity at low concentrations of 
cyclic AMP and also indicates that the cell density-dependent response is receptor 
mediated. Plotting ofthe adenylate cyclase activity as [^]-cyclic AMP (dpm)/1000 cells 
also supports that the increased response at low cell densities is real and is not an artefact 
of data manipulation (Fig 20). 
Iloprost concentration response curves (Fig. 21) at both 15,000 and 500 cells/well 
were plotted. The affinity of iloprost to the IP-receptor remained in the same 
concentration range at 15,000 and 500 cells/well (EC50 28 nM and 85 nM respectively) 
suggesting that the response is mediated via the same receptor. The efficacy of iloprost-
mediated stimulation of adenylate cyclase increased from 3.36 土 0.14 to 6.03 土 0.38 fold 
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basal cyclic AMP in the 15,000 and 500 cells/well preparations respectively, suggesting 
that there may be downregulation of the IP-receptor or an inhibitory factor present at 
higher cell densities. 
'V 
The most likely cause of this apparent downregulation of the IP-receptor and 
EP2/4-receptor mediated responses is that more endogenously produced prostacyclin or 
other prostaglandins are present at the higher cell densities. Further investigations 
revealed that the IP-receptor mediated response was not increased in the presence of 
indomethacin, suggesting that the apparent downregulation of the IP-receptor mediated 
response at higher cell densities was not due to endogenous production of prostacyclin. 
Measurement of the prostacyclin metabolite 6-keto-PGFia showed a slight decrease in 
concentration in the presence of indomethacin. However, with such a high concentration 
of indomethacin present, one would expect a much greater reduction of 6-keto-PGFia, 
therefore further work will be needed to determine whether or not this reduction is 
significantly different. 
Investigations using antagonists to other endogenously produced ligands that may 
inhibit the cyclic AMP response at higher cell densities revealed that neither adenosine 
Ai receptor antagonist or opiate receptor antagonists caused increases in cyclic AMP 
responses. The involvement of other Gj coupled agonists is also doubtful since previous 
results demonstrated that pertussis toxin failed to increase basal adenylate cyclase activity 
(section 7.1.5). 
Previous studies using UMR-6 cells and mast cells have demonstrated that 
activation of PKC causes increases in responses to both cicaprost and forskolin and a 
reduction in response to PGE2 (Khanin et al., 1999). Our studies demonstrated that PMA 
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a PKC activator, also caused a significant increase (p < 0.05) in response to forskolin but 
failed to significantly increase the cicaprost response and reduce the PGE2 response in 
adult rat DRG cells. However, despite the lack of statistical evidence, the cicaprost 
-response did show a tendency to be slightly higher after pretreatment with PMA and 
therefore warrants further investigation. 
9.8 Conclusions 
Low DRG cell densities produce significantly higher levels of cyclic AMP than higher 
cell densities in response to prostanoid mimetics iloprost, PGEi and PGE2. The apparent 
downregulation of the IP-receptor mediated response is not prevented by indomethacin, 
however, it is unclear whether or not the indomethacin significantly reduced 6-keto-
i > . 
PGFia levels in these cells. The apparent downregulation is also unlikely to be due to 
stimulation of Gj coupled receptors by endogenously produced ligands. Preliminary 
results suggest that activation of PKC does not influence IP-receptor or EP2/4-receptor 









General Discussion and Conclusions 
、 
10.1 Development of DRG cell preparation 
The establishment of the rat DRG cell preparation in this laboratory has enabled us to 
further characterise the IP-receptor in the these cells and will no doubt enable further 
research and understanding of other signalling pathways in DRG cells in the future. This 
study has demonstrated that DRG cells prepared in this laboratory are comparable in size 
and distribution to other studies (Lawson, 1979; Bowie et al, 1994; Gilabert et al, 1997). 
Immunocyctochemical studies have confirmed that the cells that were morphologically 
. identified as DRG cells are indeed neuronal, and have identified the presence of 
astrocytes in the cell preparation. Second messenger studies have demonstrated that the 
DRG cells prepared in this laboratory behave in a similar manner when exposed to 
2+ 
prostanoids regarding the production of cyclic AMP (Smith et al” 1998). The [Ca ]i 
studies demonstrated that 33% of the neurones were capsaicin sensitive and the 
neuropeptide content studies demonstrated the presence of CGRP, both indicating the 
:,i^  
nociceptive capabilities of the DRG neurones prepared in this laboratory. 
The development of this DRG cell preparation was the most time consuming of 
all the individual components of this study and took over 6 months to achieve desirable 
cell yields. Whilst numerous attempts were made to purify the DRG cell preparation 
using various purification techniques at the developmental stage, unfortunately we failed _ 
', 
: to achieve high DRG cell purity. During the developmental stage, cell yields varied I ？ 
considerably, due to lack of experience in dissecting and isolating the cells. It was 






determine which cellular purification method worked most efficiently. Now that the 
preparation is fully established and that constant cell yields can be obtained，more work 
can be conducted to obtain purer DRG cell preparations. 
'V 
10.2 Effect of prostanoid mimetics on intracellular messengers 
The effect of prostanoid mimetics on cyclic AMP production demonstrated that a number 
of prostanoid receptors are expressed in adult rat DRG cells. The high potency of 
prostacyclin mimetics, cicaprost and iloprost, in causing an increase in [^H]-cyclic AMP 
production shows that the IP-receptor is more strongly coupled to adenylate cyclase 
activity than EP2/4-receptors in adult rat DRG cells. Our desensitisation experiments 
demonstrate that the PGE2 is unlikely to be acting on the IP-receptor, since no cross-
?S . 
desensitisation was observed between iloprost and PGE2，thus confirming that PGE2 is 
unable to stimulate IP-receptors at these concentrations in these cells. Simultaneous 
activation of both EP2/4-receptors and EP3-recept0rs is also unlikely since the EP3-
receptor agonist sulprostone did not inhibit responses to cicaprost, PGE2 or forskolin thus 
confirming the previous work of Smith et al. (1998). A low number of EP2/4-receptors 
could conceivably cause the lower maximum response of PGE2. Previous studies have 
demonstrated high levels of mRNA for EP4-recept0rs in mouse (Oida et al., 1995) and rat 
DRG OSfantel et al., 1999，personal communication) but little or no mRNA for EP2-
receptors have been found. This would indicate that the EP-receptor mediated responses 
were via the EP4-recept0r. This assumption could be supported in future studies by 
incubating the DRG cells in the presence of the EP4-recept0r antagonist, AH23848B. 
The high maximum response ofPGEi suggests that this agonist may be acting via 
both IP-receptors and EP2/4-receptors as expected, since PGE! is a known agonist of both 
IP- and EP2/4-receptors in other cell types (Katsuyama et al., 1994). This theory is 
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supported by the desensitisation experiments, since cross-desensitisation was observed 
between PGEi and iloprost, and between PGEi and PGE2. 
Pretreatment of the DRG cells with cholera toxin confirmed the work ofNamba et 
�cd. (1994), that the IP-receptor was positively coupled to adenylate cyclase via Gs. 
Unfortunately the inositol phosphate production experiments did not work, therefore we 
were unable to confirm that prostacyclin mimetics were able to stimulate inositol 
phosphate production and also unable to determine whether Gj proteins mediated this 
response in DRG cells. However, preliminary calcium studies were able to demonstrate 
that iloprost was able to stimulate increases in [Ca^ ]^i thus confirming that the IP-receptor 
is able to stimulate the PLC pathway. 
10.3 Regulation of prostacyclin receptors 
Studies to investigate the regulation of IP-receptor mediated responses revealed that cells 
plated at lower cell densities (500 cells/well) produced significantly greater cyclic AMP 
levels in response to iloprost than cells plated at higher cell densities (15,000 cells/well). 
This was also found to be the case with responses to PGEi and PGE2 but not to forskolin. 
^ Incubation of the cells for 5 days in the presence of indomethacin failed to cause an 
5 V 
increase in cyclic AMP levels suggesting the apparent downregulation of the EP- and IP-
| . ‘ ！ 
1-
receptors was not due to endogenous production of PGE2 or prostacyclin. However, 
I 
attempts to measure the prostacyclin metabolite 6-keto-PGFia were inconclusive. As with 
� the other EIA performed in this laboratory, the assay gave inconsistent results and often 
. the standards supplied in the kit appeared to be denatured. A single successful experiment 
indicated that indomethacin only slightly reduced the level of endogenous prostacyclin, 
suggesting that the concentration of indomethacin was not sufficient. Further experiments 
with different batches of indomethacin and 6-keto-PGFia standards from other sources 
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should be conducted in the future to clarify the situation. Measurement of endogenous 
PGE2 levels following indomethacin pretreatment could also be conducted. 
Treatment of the DRG cells with pertussis toxin and antagonists to Gi coupled 
�receptors demonstrated that the decreased cyclic AMP response in higher cell densities 
was unlikely to be due to production of endogenous G[ coupling agonists such as 
adenosine or opiates. Whether or not this cell density-dependent response is only seen 
with prostanoid receptor mediated cyclic AMP response is currently under investigation, 
and preliminary results suggest that isoprenaline and salbutamoI (p-adrenoceptor 
agonists) do not cause an increase in cyclic AMP response due to decreased cell density. 
This would indicate that only prostaglandin receptors undergo this apparent 
downregulation of responses at higher cell densities, thus further indicating that it is 
K! . 
endogenous prostaglandins that are responsible. 
The involvement of PKC has been implicated in the regulation of prostanoid 
receptor mediated responses in cells such as UMR-106 osteoblasts and in cultured mast 
cell and also recently in adult rat DRG cells (Smith et al, 1998; Khanin et al., 1999). In 
all three different cell types a phorbol ester derivative caused an increase in prostacyclin 
and forskolin mediated cyclic AMP suggesting that PKC activation can modulate the 
adenylate cyclase system. The exact mechanism of action is unclear but may be due to 
increase in adenylate cyclase sensitivity or may be due to phosphorylation of Gj-coupled 
receptors to attenuate tonic inhibitory activity (Smith et al., 1998). The latter is unlikely 
, in DRG cells since our studies have demonstrated that inhibition of Gi-mediated 
responses does not cause increased adenylate cyclase activity. In our studies，the phorbol 
ester derivative PMA failed to cause a significant increase in the cyclic AMP response to 
cicaprost although there was a tendency for the response to increase in the presence of 
PMA and is therefore worth further investigation. However, as with previous studies 
110 
(Smith et al, 1998; Khanin et al, 1999) PMA did cause an increase in forskolin-
stimulated cyclic AMP production. Previous studies have also reported that, PGE2 
mediated cyclic AMP responses in the presence of phorbol esters were decreased, 
�suggesting that EP2/4-receptor mediated responses are regulated differently to IP-receptor 
mediated responses (Khanin et al., 1999). However our result indicate that PKC 
activation has no effect on PGE2-mediated cyclic AMP responses. 
10.4 Role of prostacyclin in pain modulation 
Investigations into the role of prostacyclin in pain modulation centred on neuropeptide 
release studies since the measurement of direct release of neuropeptide by prostacyclin 
would prove that prostacyclin can cause direct nociception, whilst enhancement of the 
response to bradykinin would confirm that prostacyclin was involved in hyperalgesia. 
However, no neuropeptide release was detected in response to neither high concentrations 
of KCl, bradykinin, capsaicin or iloprost. This could have been due to the absence of 
nociceptive neurones in our DRG cell preparation or due to poor assay sensitivity. The 
former conclusion is unlikely since a high level of CGRP was found in the DRG cells, 
suggesting nociceptive capability. Also, preliminary [Ca^ ]^i studies revealed that 33% of 
all cells identified as neuronal by KC1 challenge responded to capsaicin, suggesting that 
• 2+ 
these were indeed nociceptive neurones. Furthermore, iloprost caused increases in [Ca ]i 
in 750/0 of the neurones that responded to both KC1 and capsaicin, therefore suggesting 
that prostacyclin may be capable of causing direct release of neuropeptides via the PLC 
pathway. Further attempts at neuropeptide release studies will have to be made to confirm 
this assumption possibly using RIAs as opposed to EIAs. More work using the Ca^ ^ 
imaging equipment should also be conducted to determine concentration-response 
relationships ofprostanoid agonists to changes in [Ca^ \ The Ca�+ imager has enormous 
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potential to clarify the role of prostacyclin in pain modulation since it is able to 
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